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Abstract 
There is an urgent need to reduce reliance on hypodermic injections for 
many protein-based therapies. Alternative approaches include developing 
controlled release formulations, which reduce dosing frequencies, and utilizing 
alternative delivery devices, such as microneedles. This thesis explores the 
development of controlled release microparticles made of poly(lactic-co-glycolic 
acid) (PLGA) that encapsulate stable/active proteins. These microparticles are 
then delivered via novel microneedle patches. This work has great implications 
for improving the utility and coverage of protein-based vaccines. 
PLGA microparticles are loaded with protein through a novel approach 
termed active self-healing encapsulation (ASE). This method loads proteins after 
microparticle fabrication, thus preventing protein exposure to a variety of 
stresses. ASE utilizes a protein trapping agent (Alhydrogel), along with the self-
healing of microparticle surface pores to sequester and trap proteins inside the 
microparticles. The self-healing phenomenon was explored in detail, and was 
determined to be a viscoelastic response of the polymer to high surface tension 
when above the glass-transition temperature (T
g
). The healing kinetics followed 
expected Williams-Landel-Ferry behavior, and Arrhenius plots generated 
activation energies consistent with polymeric creep. A mathematical model to 
predict healing times is also presented. 
xix 
 
The ASE technique afforded high loading (1.64% w/w) and encapsulation 
efficiencies up to 91% for the model protein Ovalbumin. In vitro controlled 
release was shown to be biphasic, with an initial release of soluble protein 
followed by a delayed release of Alhydrogel-complexed protein over the course 
of two months. Furthermore, a bulk batch of microparticles can be used to load 
many different proteins without needing to reformulate unique batches. 
A process was also designed to deliver protein-loaded microparticles via a 
microneedle patch. Microneedle patches can be easily self-applied, are easy to 
store/dispose, and are generally preferred by patients over traditional 
hypodermic needles. These patches, made of a dissolvable material, 
successfully delivered microparticles intradermally where they began antigen 
release. In animal models these patches generated a robust immune response 
that was as good as or better than conventional administration techniques. 
This thesis lays the ground work for a versatile system for delivering 
protein-based vaccines with reduced dosing requirements or limited need for 
hypodermic injections. 
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Chapter 1:  Introduction 
1.1 Controlled Release 
 
Very few therapies can be given once and have long-lasting or lifelong 
effects. Instead, most drugs demonstrate effectiveness only when their 
concentration at a particular site in the body is between some therapeutic 
window. Below this window, the patient does not experience any benefits, and 
above it the drug may begin to demonstrate deleterious side effects. In order to 
maintain drug concentrations within this therapeutic window, many therapies 
are given on a schedule. Common examples in oral medication are pain 
relievers and birth control medicines, while insulin injections represent the 
most common parenteral therapy. In both cases, the drug concentration rises 
after administration to therapeutic levels, but begins to drop after complete 
absorption until the process must be repeated. 
While seemingly simple, the obstacles to scheduled dosing are numerous. 
For example, inconvenient dosing intervals, busy lifestyles styles, physical 
inabilities, and cost can all lead to decreased patient compliance. If the patient 
misses a dose, the drug concentration drops out of the therapeutic window and 
the treatment stops working. To overcome these obstacles, scientists have 
developed a variety of controlled release drug delivery (CRDD) systems that are 
designed to maintain therapeutic concentrations after a single dose for longer 
than would be possible with conventional drug products.  
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One area in particular where CRDD is desperately needed is treatments 
with biomacromolecules, such as proteins, antibodies, or nucleic acids. While 
small molecules like birth control drugs can be taken orally, biomacromolecules 
are degraded during oral administration and/or have poor gastrointestinal 
absorption, and must therefore be dosed via injection. Repeated injections can 
be painful, costly, cause psychological stress, and produce large amounts of 
biohazardous waste. Although there are many approaches to achieving CRDD, a 
long-studied approach is through the use of polymer systems that control the 
rate of drug release via a variety of internal and external mechanisms. While 
many of these have been used experimentally, only a few have seen approval 
and success on the clinical market. 
1.1.1 PLGA 
 
Poly(glycolic acid) was one of the early polymers used as a 
biodegradable/bioresorbable suture (1). To increase the suture half-life, the 
more hydrophobic lactic acid, with its sterically hindered ester bond, was later 
added to make poly(lactic-co-glycolic acid) (PLGA) (Fig 1-1). PLGA’s history as a 
safe and biodegradable polymer stems from the biochemistry of its monomers, 
lactide and glycolide. These soluble acids are released as PLGA degrades 
through spontaneous chain cleavage caused by hydrolysis (2). Both monomers 
are viewed as natural products to the body, and are shuttled into normal 
biochemical processes. Lactic acid enters the Cori Cycle along with that 
produced by fermentation in the muscles and is converted to glucose in the 
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liver. Glycolic acid is either degraded to oxalic acid or malate, which then enters 
Krebs cycle (3). 
Researchers soon found that by altering the ratio of lactide and glycolide, 
along with the molecular weight (Mw) of the polymer chains, the end-groups, 
and the concentration, degradation times could be tailored to the needs of the 
specific device – with release profiles lasting between days and years. PLGA has 
been used in a litany of FDA-approved products including bone regeneration 
scaffolds, cardiovascular stents, films/patches, and in situ forming gels (4). This 
has led to PLGA’s success and popularity as a polymer for CRDD.  
 
Figure 1-1: Molecular structure of PLGA. * denotes the sterocenter of lactide. 
 
1.1.1.1 PLGA Microparticles 
 
Perhaps the most common use of PLGA is as nano- or microparticles 
loaded with drug. These are small particles, typically spheres, of the polymer, 
which can be solid, contain cavities/pores, or be coated in other materials. As 
the polymer undergoes bulk degradation (in addition to other mechanisms) the 
payload is slowly released. A variety of techniques are available for making 
microparticles, but the most popular are emulsion or phase-separation  
based (5) (Fig 1-2). Here, the hydrophobic polymer is dissolved in an organic oil 
* 
* 
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phase. The oil phase is then added to a non-solvent (often water) with an 
emulsifying agent (such as poly(vinyl alcohol) (PVA)). The mixture is then 
stirred to evaporate the solvent, leaving behind hardened polymer particles. If 
the drug is hydrophobic (typical of small molecule drugs), then it can be 
dissolved along with the polymer in the oil phase, and the emulsion is a simple 
oil-in-water (o/w) type. If the drug is hydrophilic (typical of proteins), it is first 
dissolved in an inner-water phase, which is then homogenized into a larger 
volume of the polymer phase before that is added to the even larger aqueous 
bath solution. The result is a water-in-oil-in-water (w/o/w) emulsion. Other 
seldom used techniques include spray drying, melting/grinding, or supercritical 
fluid extraction (5). 
 
Figure 1-2: Double-emulsion fabrication process for PLGA microparticles. Modified from Ref. (6) 
 
Mechanisms of Controlled Release from PLGA Devices 
 
The manner in which PLGA microparticles release drug is dependent on 
many factors, and the rate-limiting process can change during the course of 
release. For certain low molecular weight drugs with similar solubility 
parameters to PLGA, the molecules may be able to directly diffuse out of the 
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polymer matrix. For other small molecules that do not dissolve in the polymer, 
and for all larger molecules, bulk erosion of the polymer microparticle must 
occur for the drug to be released (5). To begin the erosion process, water slowly 
diffuses into the polymer phase and molecular degradation occurs throughout 
the microparticle (rather than just at the surface). When the polymer chains 
reach a critical length, they become soluble and diffuse out of the microparticle 
through aqueous microchannels created by degradation.  
When working with proteins or other larger hydrophilic 
biomacromolecules, the microparticles are usually made from a double-
emulsion containing an inner water phase in which protein will reside (Fig 1-2). 
This inner-water phase creates a pore network that percolates throughout the 
bulk of the microparticle. For such microparticles, release is typically 
dependent on diffusion of protein out of these pores. If the pores are 
exposed/open on the surface of the microparticle, the protein can diffuse out. 
Thus, release is limited by both the rate of diffusion through these pores, and 
by the opening of the pores to the environment, which can also be dependent 
on the degradation kinetics of the polymer (7). 
Another feature that has made PLGA such a useful polymer is its glass-
transition temperature (T
g
). The glass-transition is a feature of amorphous 
materials like PLGA. Unlike crystalline materials, amorphous materials do not 
have a long-range ordered structure; the molecules of an amorphous material 
tend to be arranged more randomly. When well below the T
g
, polymer 
backbones are largely locked into their conformation, and the material is 
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referred to as a glass. Glasses tend to be brittle and highly viscous materials. 
Above the T
g
, the molecules have improved mobility, and the material (now 
referred to as a rubber) is soft, malleable, and less viscous. The transition from 
glass to rubber is reversible and time-dependent, but is not a true phase-
transition – the material remains a solid without translational molecular 
movement. As the chains gain mobility, the heat capacity of the material 
changes, allowing the transition to be recorded on a calorimeter. Many factors 
can affect when a polymer will undergo a glass-transition, including Mw and the 
degree of cross-linking or branching. Encapsulated drugs, excipients, solvents, 
and especially water can all act as plasticizers by increasing the free volume – 
essentially lubricating the polymer chains and dropping the T
g
(8). In general, 
mechanisms such as hydration, degradation, and pore opening/closing do not 
occur with significant speed below the T
g
, making it a critical feature to 
controlled release.  
This feature is relevant for PLGA CRDD systems because the T
g
 of most 
hydrated PLGAs are just below body temperature; while dry it is well above 
normal ambient temperatures. This means that when stored on the shelf the 
chains cannot move, increasing the shelf-life and preventing serious 
morphological changes. Only when applied in vivo do the polymer chains begin 
to move, accelerating degradation and beginning drug release. 
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Limitations to Encapsulating Biomacromolecules 
 
While some PLGA delivery systems have seen success on the market, 
several obstacles still limit their potential for future therapies. Sensitive 
biomacromolecules (henceforth generalized as proteins) have proven 
particularly challenging to deliver, which should be of great concern as 
pharmaceutical development becomes increasingly biologic. From formulation 
through release, there are many potential causes of protein instability. During 
microparticle manufacturing, for example, the emulsion is stirred quickly, 
creating high shear stresses and exposing the protein to large water-solvent 
interfaces, both of which are known to be sources of irreversible protein 
aggregation (9, 10). Furthermore, for use in humans, drug delivery systems 
must be sterile. Since maintaining aseptic manufacturing conditions of sterile 
starting materials is often cost-preventative, PLGA microparticles are usually 
terminally sterilized with γ-irradiation (11). The heat and energy imparted 
during this process can cause further disruption of protein structure (12). 
Additional limitations are damage caused during freeze-drying to increase 
shelf-life, and the relatively high cost of manufacturing PLGA (13). Therefore, 
there is significant need for an encapsulation paradigm that limits protein 
exposure to harmful conditions, and that limits the amount of PLGA and 
protein required for use. 
A complication shared by both proteins and small molecules encapsulated 
in PLGA microparticles is high burst release (7). During this phase, a significant 
amount of drug is released during the early stages of incubation, occasionally 
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as high as 80% within just the first day (4). Since the goal of CRDD is to 
maintain therapeutic concentrations over an extended period, too much drug 
released over a short period of time is counterproductive. Not only does this 
beget the potential to increase concentrations above the therapeutic window 
and cause toxicity, it also limits the lifespan of the therapy and necessitates re-
dosing earlier than maybe desired. While burst release has historically been 
attributed to liberation of drug from the surface of the microparticles (14), 
mechanistic research suggests that it may instead be controlled by the 
spontaneous opening and closing of the surface of the pore network where 
solubilized drug resides (15, 16). 
Pore Behavior and Utility in PLGA Microparticles 
 
As previously mentioned, PLGA microparticles often contain an aqueous 
pore network. This is most prominent when working with microparticles 
created via a w/o/w double-emulsion. When creating the emulsion, the inner 
water phase forms droplets within the polymer solution. Typically, this inner 
water phase will contain the dissolved proteins, along with excipients such as 
sugars and salts that may be included for stability purposes. These dissolved 
solutes create an osmotic force inside the microparticles. When the two inner 
phases are added to the final outer water phase, if the outer water phase is not 
osmotically balanced to the inner water phase, the osmotic pressure difference 
can rupture or crack through the polymer, thus creating an opening to the 
pores on the surface (a surface pore) (4). Other pores are also formed when the 
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solvent leaves the polymer phase during both solvent evaporation and freeze-
drying. 
When the finished microparticles are again introduced into an aqueous 
environment (e.g., during release), these pores fill with fluid, redissolving any 
protein and excipients present. Again, since these entities generally cannot 
diffuse into or through the polymer, the rate-limiting step to their release is the 
diffusion through the pores and out of the microparticles. However, it has been 
noticed that the surface of these pores are not static. Rather, they appear to be 
capable of opening and closing (or vice versa) during release/incubation. In 
general, it has been noticed that in the early stages of release the pores may be 
open, either occurring during microsphere preparation or as a result of water 
entering and swelling the microparticles during the initial burst phase. After 
some period of time, however, the pores spontaneously close and the 
microparticles becomes smooth (7, 16). The time window over which this 
process occurs appears to closely match the beginning and end of the initial 
burst release phase (7). Thus, it appears plausible that rather than release of 
unencapsulated protein from the surface, initial burst release may actually be 
caused by the rapid diffusion of protein out of the open pores, and its 
cessation is caused by the healing of said pores preventing further protein from 
escaping. For some period of time, the microparticles remain smooth, which 
appears to correspond to the lag phase where little to no protein is releasing. 
Then, in the final stages of release the polymer physically degrades and new 
pores form as the microparticles fall apart, allowing the remaining cargo to be 
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released. In summary, it appears that in the case of biomacromolecules, the 
physical behavior of these polymer pores can be the rate-limiting step to 
release. However, the mechanisms and driving forces that govern pore behavior 
are poorly understood. On a final note, evidence suggests that the healing of 
the pores only takes place above the T
g
 (17). This indicated there is a polymer 
chain mobility component, and that the rate of healing/opening may depend on 
the physical-chemical properties of the polymer. 
The mechanism by which the surface pores of PLGA heal-over has not been 
well studied, and it remains unclear to what extent various forces drive the 
process. It is currently hypothesized that PLGA microparticles have high 
surface/interfacial tension in air and water, respectively, caused by the solvent 
evaporation process. When the polymer is raised above T
g
 the chains are able to 
relieve this stress by rearranging via reptation to minimize the surface area, 
thus healing the pores. In this way, self-healing could be considered a form of 
creep (18). If true, then the rate of healing would be dependent on the 
viscoelastic properties of PLGA (such as Young’s Modulus) and healing kinetics 
should fit the Williams-Landel-Ferry equation (WLF) of time-temperature 
superposition. This equation states that since viscoelastic moduli decrease 
predictably with temperature, a shift factor exists that allows data from 
viscoelastic experiments performed at different temperatures to superimpose 
(18).  
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Passive Self-Encapsulation 
 
After the discovery that healing of surface pores can trap proteins inside 
PLGA microparticles and prevent their release, it was proposed that the closing 
of these pores could be used to entrap drugs inside the microparticles as a new 
loading paradigm (19). In this strategy, called self-healing encapsulation, 
porous PLGA particles were created via a double-emulsion without protein 
present. This made “blank” or empty microparticles. These microparticles were 
then incubated in a protein solution and the temperature was slowly ramped 
from 4 to 42 °C (above T
g
). The microparticles were then washed and analyzed 
for protein content. Indeed it was found that microparticles could be loaded in 
this fashion, and the amount of drug encapsulated in the microparticles 
increased linearly with the protein concentration of the loading solution and 
the porosity of the microparticles. This approach is unique in that it does not 
expose the proteins to the conditions used to fabricate the microparticles.  
Prior to loading, the microparticles were porous, but afterwards they were 
smooth. Furthermore, when the microparticles were reintroduced to a release 
solution at 37 °C, the pores slowly reformed and the protein was released over 
several days. Of significant importance however, was that because the pores 
were closed at the beginning of release, a severe attenuation in initial burst was 
observed. Instead, the microparticles demonstrated more linear early-phase 
release kinetics. 
While this development was promising, it carried two serious caveats. First, 
since the pores were simply equilibrating with the protein loading solution, but 
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the volume of the pore network was much lower than the overall loading 
solution, there was poor encapsulation efficiency (~30%). Given the cost of 
many protein drugs, this made the strategy interesting, but not useful. 
Additionally, in order to achieve useful loading (>1%), very high protein 
concentrations were required – upwards of 240 mg/mL. Such a system is not 
translatable to all biomacromolecules, as solubility and aggregation 
complications may arise at such high concentrations. 
Active Self-Encapsulation  
 
To overcome the limitations mentioned above, investigators sought a way 
to sequester proteins exclusively inside the microparticles rather than relying 
on diffusion/equilibration from a loading solution. If a trapping agent could be 
included in the microparticles, it would provide a driving force to draw protein 
from solution into the microparticles, thus wasting less protein (improve 
encapsulation efficiency) and allowing the use of lower concentrations (Fig 1-3). 
This technique, referred to as Active Self-Encapsulation, is currently being 
investigated with a variety of trapping agents. The trapping agent selected 
depends primarily on the protein of interest, but is some entity that will bind to 
the protein. Examples of trapping agents include zinc complexes, biopolymers, 
and metal-based vaccine adjuvants (20, 21). Of focus here will be the vaccine 
adjuvant class, particularly aluminum hydroxide gel (Alhydrogel). More detail is 
provided on Alhydrogel in future sections, but it is known to bind many 
negatively charged or phosphorylated proteins. It has excellent adsorption 
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capacity, up to 3 mg protein/mg Alhydrogel (22). By including this in the 
microparticles, very little unencapsulated protein is left in the loading solution 
(up to 98% encapsulation efficiency) (21). 
The potential of Active Self-Encapsulation is its ability to separate proteins 
from the damaging aspects of manufacturing mentioned previously. Now, 
microparticles can be prepared and sterilized in the absence of protein, stored 
in bulk, and loaded only when needed at the point of care (i.e., at the pharmacy 
or in the field). This paradigm can also significantly reduce costs since more of 
the protein in the microparticles is in the therapeutic state. Moreover, the 
absence of a large initial burst and a longer delivery lifetime means less 
frequent and safer dosing. Finally, since Alhydrogel binds to many different 
proteins, the same parent batch of microparticles can be used to load a variety 
of different proteins. 
 
          Figure 1-3: Schematic of Active Self-Encapsulation system. From Ref. (21) 
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1.2 Vaccination  
 
The concept of intentionally manipulating the immune system to prevent 
future diseases dates back several millennia and is often considered to be the 
single greatest advancement in the defense against disease (23). Active 
immunization is the process where an individual is intentionally exposed to a 
pathogen-derived antigen to prime the adaptive immune response before any 
infection actually develops.  
There are several types of vaccines, each with distinct advantages and 
disadvantages. The first type heavily used in the USA was Salk’s killed 
(inactivated) Poliomyelitis vaccine. This was a fully inactivated pathogen. When 
injected, no infection develops; instead, antigen-presenting cells (APCs) engulf 
the antigen, and a humoral immune response begins. Because there is no 
infection, the immune response is weak and lacking cell-mediated aspects. 
Several boosters are needed to fully develop and maintain humoral memory. 
To create a stronger immune response, Saban’s Polio vaccine contains a 
whole but partially attenuated form of the virus. When injected, a transient 
infection develops that does not demonstrate the symptoms of the disease. 
This leads to a strong humoral and cell-mediated response requiring fewer 
(typically only one) boosters. The drawback of this vaccine class is the chance 
that the virus will revert to its fully infectious form and cause the disease it is 
designed to prevent (24). Modern vaccines in development are attempting to 
use purified recombinant proteins or DNA from pathogens. While the hope is 
these may lead to new treatments that can provide both cell-mediated and 
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humoral immunity with no chance of reversion, they have thus far proved 
poorly immunogenic, and very few ‘modern’ vaccines have been approved for 
use, with ‘old school’ vaccines still dominating the market (25). 
1.2.1  Vaccine Adjuvants 
 
Not all vaccines (particularly those that do not establish infection) properly 
stimulate immune cells. Early researchers noticed this when they added 
blended bits of bacteria to purified antigen and the response improved (26). 
Now referred to as adjuvants, these are any materials that enhance the immune 
response towards a vaccine. In modern vaccinology, adjuvants also help 
stabilize antigens during storage and administration (26). 
Currently, the most common type of adjuvants approved for human use in 
the USA are salts and gels based on aluminum (27). The exact mechanism 
through which these work is still hotly debated, but can be summarized briefly 
into three processes: (A) extends residence time of antigen in tissue through 
slow release from the gel surface, (B) creates a particulate, rather than soluble 
form of antigen that is easier for APCs to engulf, (C) aluminum causes 
inflammation, recruiting immune cells to the antigen (22, 26). A common 
adjuvant, aluminum hydroxide gel (henceforth referred to as Alhydrogel) is a 
colloidal suspension of aluminum oxyhydroxide. It carries a positive charge 
below pH ~10.5, so it can electrostatically adsorb to many negatively charged 
proteins (28). This reaction is reversible through changes in pH or by 
outcompeting the adsorption with a strong co-ion (such as phosphate or 
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succinate). Also, because aluminum has a very high affinity for phosphate, 
Alhydrogel can undergo ligand exchange with the phosphate groups of 
phosphorylated proteins. This reaction is much stronger, and generally 
irreversible. When bound to Alhydrogel, the protein conformation is locked, 
and the protein-Alhydrogel complex takes on a colloidal state. 
Despite its usefulness, Alhydrogel is also very sensitive. Freezing results in 
nearly complete loss of antigen binding. This is caused by ice crystals putting a 
compressive force on the particles – overcoming their surface repulsion and 
causing aggregation. Furthermore, the particles lose their internal water phase 
and settle (28-30). To protect Alhydrogel, it can be frozen by quick submersion 
in liquid nitrogen (29-30). This creates smaller, more numerous ice crystals 
than would form during a slow freeze. Additionally, a glass forming excipient 
such as the sugar trehalose can be included. This disrupts the hydrogen bonds 
of water and creates an amorphous glassy phase in which crystals do not 
properly form, thus protecting the Alhydrogel particles. Multiple studies have 
shown that when trehalose is included with Alhydrogel, aggregation of the 
particles is almost completely avoided (31, 32) 
1.2.2  Controlled Release Vaccination Systems 
 
The necessity of boosters in modern vaccines is one of the biggest hurdles 
to complete elimination of diseases for which vaccines currently exist. They are 
required because of the poor immune response to killed or purified vaccines 
leads to low numbers of poorly binding antibodies. In some cases, five or more 
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boosters are required before protective immunity develops. Reintroducing the 
antigen helps strengthen the antibody response, but also increases costs and 
patient discomfort, while decreasing compliance (33). To decrease reliance on 
boosters, researchers are investigating Single Administration Vaccines (SAVs). 
Early research in this field attempted to mimic the booster schedule of discrete, 
pulsatile release patterns via programmable implants or controlled release from 
distinct sections of a device (34, 35). However, it has been shown for decades 
that continuous antigen delivery can also serve to improve the immune 
response, and that the kinetics of antigen presentation significantly affects the 
strength of the response (36, 37). 
PLGA microparticles have received much interest for their potential in 
SAVs. In fact, PLGA itself is considered a possible vaccine adjuvant because it 
demonstrates potential to elicit a CD8+ cell-mediated response while also 
encapsulating the antigen without showing toxicity (33). While the controlled 
release potential of PLGA SAVs is enticing, these systems have thus far been 
plagued by the stability and cost concerns mentioned in Section 1.1.1.1, 
preventing them from serious human use. It has yet to be seen whether the 
addition of stabilizing excipients, along with the Active Self-Encapsulation 
paradigm, may allow PLGA to be used in a SAV device.  
1.3 Microneedles for Drug Delivery 
 
As the pharmaceutical field has become more advanced, there has been a 
push away from the once ubiquitous small-molecule drugs towards larger 
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biologics such as proteins, peptides, and DNA/RNA. However, these 
macromolecules are typically poorly absorbed and/or degraded in the 
gastrointestinal tract and liver (38). To overcome this, an increasing percent of 
medications, including many of the CRDD-types mentioned above, are relying 
on hypodermic needles for delivery. However, the hypodermic needle is a less-
than-optimal delivery system. It is difficult to use (typically requiring a trained 
professional), painful, often fear-inducing, and risks spreading blood-borne 
pathogens if not disposed of properly. So, in the late 1990s scientists thought 
to shrink needles down to the micron scale to meet many of these challenges, 
and the field of microneedle drug delivery was born. 
Primarily, four different types of microneedles exist (Fig 1-4). The first 
style created was solid metal microneedles. These are made from strong 
materials such as steel or silicon. Their purpose is not to deliver drugs 
themselves; rather they pierce the dense and impermeable upper layer of skin 
and create microchannels. When drug is applied later, either from a patch-
based fluid reservoir or topical cream, it diffuses into these channels to enter 
the skin and/or dermal vasculature (39, 40). The next system developed was 
coated microneedles. The underlying structure here is the same as solid 
microneedles. However, before administration the microneedles are coated with 
a drug solution and then dried. The mechanical strength of the base material 
allows the microneedles to penetrate the skin, introducing the drug coating to 
the hydrated lower layers where it rapidly dissolves (40, 41). A number of 
therapeutics have been experimentally delivered using coated microneedles, 
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including protein and DNA vaccines (42). Since not all formulations are stable 
when dried, the next category of microneedles attempts to more directly mimic 
hypodermic needles. These microneedles have a hollow center through which 
drug can be delivered just past the upper layer of skin. This system allows 
specific amounts to be manually delivered via a syringe attached to the 
microneedles’ backing (43), or can be diffusion-driven from a reservoir (44). 
Studies have shown that up to 1 mL of fluid can be injected with only mild pain 
(40). The final microneedle category is those made entirely from biocompatible 
compounds that erode when pressed into the skin to release encapsulated 
drugs. Often made from water-soluble polymers or sugars, the material is 
mixed with the drug and dried into a mold or melted and cast. After 
application, the microneedles dissolve/degrade and the drug is released into 
the skin where it can act directly or diffuse into the vasculature. Since all the 
material that has entered the skin remains there, this type has great potential 
to reduce biohazardous waste (40). There have also been combinatorial 
approaches, which utilize a sort of pedestal and arrow-head to lengthen the 
microneedles and help them better insert into the skin. In these cases the 
backing materials and pedestal may or may not be soluble, but the microneedle 
itself rests on the pedestal and dissolves more fully in the skin. This also helps 
reduce the amount of time the patch must remain on the skin, as the 
arrowhead may separate from the backing for extended dissolution (45).  
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Figure 1-4: Various microneedles. A & B) Solid metal, C & D) Coated, E & F) Hollow,  
G & H) Soluble. From Ref. (40) 
 
1.3.1 Anatomy of the Skin 
 
The skin is the largest organ of the body, accounting for 10% of total body 
mass (41). It allows terrestrial life to exist by “keeping our insides in, and the 
outside out”. While many consider it a simple static barrier, it is surprisingly 
dynamic and consists of separate well-defined layers. The deepest level is the 
hypodermis. This is a layer of subcutaneous fat between organs/muscles and 
the skin. It helps insulate the body and serves as an energy store. Above this is 
the dermis, which ranges between 3 and 5 mm thick in humans. The dermis is 
predominantly collagen and fibroblast cells, and is very hydrated to the point 
of sometimes being considered gelled water. This is the uppermost layer for 
blood, lymph, and nervous tissue, and the base for hair follicles and sweat 
glands. Apical to the dermis is the dermo-epidermal membrane, which 
separates the dermis from the epidermis. The epidermis ranges between  
60-800 µm (average ~80 µm) and is composed mostly of avascularized 
keratinocytes. These cells are loosely bound together with desmosomes, with 
the basal layer bound to the dermo-epidermal membrane. Only the most basal 
monolayer of cells divide, with daughter cells being pushed up with each 
division. As cells move to the surface, they lose cellular functions, eventually 
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becoming part of the top layer, the stratum corneum (SC). The SC is ~10 µm 
thick, and is a very dense layer of dead keratinized cells embedded in a lipid 
matrix. The brick-and-mortar makeup of this layer prevents absorption of 
hydrophilic substances or penetration of large molecules. It is the rate-limiting 
layer to trans/intradermal drug delivery and absorption, with no useful cellular 
activity (41). 
The skin also hosts a variety of different cells and molecules, both resident 
and recruited. Like the gut, it is home to a diverse non-pathogenic microbiome. 
The cells and extracellular fluids have also been estimated to have an 
enzymatic capacity roughly 5% that of the liver. Finally, the skin has a powerful 
immune system capable of operating on its own and in coordination with the 
rest of the body (41). 
1.3.1.1 The Skin Immune System 
 
It is intuitive that the body would put such a strong immunologic focus on 
the skin, as it interacts the most with the outside word. Early man evolved the 
immune system by stepping on rocks and scraping against bushes, and 
required skin immunity to survive past infancy. It is now projected that half of 
all cells present in the skin have some immunologic function, and the phrase 
skin-associated lymphoid tissue (SALT) is used to describe their interactions (46). 
The most immunogenic cells are dermal dendritic cells (DCs), and their 
epidermal subset, Langerhans cells (LCs). Both are phagocytic antigen 
presenting cells (APC)s, but LCs are found only in skin and mucosa, making up 
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3-5% of epidermal tissue (47). They are voraciously phagocytic and, like DCs, 
express Toll-like Receptors (TLRs) to identify pathogens via pathogen-
associated molecular patterns (PAMPs). After ingesting an antigen, LCs and DCs 
enter lymphatic vessels located in the dermis and travel to skin-draining lymph 
nodes. There they mature and express the antigen on MHC I and/or II receptors 
to lymphocytes circulating in the lymph node – beginning the adaptive 
response (26). There is also a native T cell population that is estimated to be 
larger than that in peripheral blood (46). 
Cells of the innate immune system also reside in the skin. Histocytes are 
resident macrophages that exist in both the dermis and epidermis and act as 
professional phagocytes and APCs. The abundant keratinocytes express TLRs, 
and react to pathogens by releasing inflammatory cytokines, which recruit non-
native inflammatory cell and T cells to the skin (46, 48). 
1.3.2  Intradermal Vaccination via Microneedles 
 
Because of its powerful immune system, the skin is a potent site for 
vaccination, and microneedles are poised to become the new standard in 
intradermal (i.d.) vaccination.  While the i.d. route is mankind’s oldest form of 
immunization, it has mostly lost ground to intramuscular (i.m.) and 
subcutaneous (s.c.) delivery. Only the Mantoux technique remains common, 
which is used in the tuberculin “skin bump” test. However, this requires a high 
degree of skill to perform, as it utilizes a small-gauge needle inserted at an 
acute angle into the skin so as to not pass through the dermis. Smallpox 
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vaccines were also dosed i.d. using a special bifurcated needle that held vaccine 
between two prongs. The needle was repeatedly stabbed into the skin in a 
sacrificial technique to dose the antigen (49). The problem facing i.d. 
immunization is that while the skin is prevalent, its thinness makes it a difficult 
site to properly administer to. I.m. immunization, despite its flaws, is simple to 
perform. Microneedles, however, are specifically designed to overcome this 
challenge. 
Several studies have suggested that i.d. immunization, including that from 
microneedles, may in fact be superior to the i.m. or s.c. routes. While those sites 
are easier to deliver to, they have lower concentrations of APCs. Antigen that is 
not presented on APCs does not contribute to immunological memory and is 
degraded. Since the skin is packed with APCs, less antigen is wasted and a 
smaller dose can be used to generate an equivalent response. Multiple clinical 
studies have shown that the when delivered i.d., a 1/5th dose of influenza 
vaccine demonstrates similar or better results than a full i.m. injection (50, 51). 
Indeed the currently approved i.d. seasonal influenza vaccine, Fluzone I.D.® uses 
40% less antigen than its i.m. counterpart. This device is a hollow microneedle 
that delivers an i.d. injection. In a separate study, when dried influenza virus-
like particles were delivered using coated microneedles, the antibody levels 
were a full order of magnitude higher than the standard i.m. vaccination. Upon 
a second challenge, the recall antibody levels were also higher, and in vivo virus 
titers were lower (52). This suggests that the site of administration may be 
important even for systemic immunity. 
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In addition to the physiologic benefits, many experts agree that intra- or 
transdermal vaccination has logistical benefits, especially in mass or immediate 
vaccination campaigns. Current stockpiles contain millions of glass vials of 
vaccine solution stored in refrigerated warehouses, and must be kept cold 
during transportation. They also require trained personnel to administer the 
vaccine and dispose of the needles. It is estimated that storage, delivery, 
administration, and clean-up represent 80% of the cost of vaccine programs. 
However, a self-administered and freeze-dried vaccine, such as those tailored to 
the i.d. route, may help control these parameters while also decreasing the time 
required to get the treatment to populations in need, thus increasing the 
country’s resiliency to mass vaccination scenarios (51).  
1.4 Thesis Outline 
 
The preceding sections highlight two important topics that require further 
research. First, there are large gaps in the understanding regarding the self-
healing phenomenon observed in PLGA microparticles. If the self-encapsulation 
technique previously mentioned is to be commercially employed, a more 
mechanistic awareness will be required. Second, as microneedles are a relatively 
new technology, there is great opportunity to utilize them in novel ways; 
particularly with regards to intradermal vaccination. This work will explore 
three connected topics. First, there will be a mechanistic evaluation of self-
healing in PLGA. This enhanced understanding will then be used to further 
explore the potential of Active Self-Encapsulating PLGA microparticles for the 
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controlled release of stable vaccine antigens. Finally, this microparticle 
technology will be translated to a microneedle system for intradermal 
vaccination without the use of hypodermic needles. 
In Chapter 2, a model system is developed for studying self-healing in 
PLGAs. This system removes many of the complexities involved with studying 
surface morphology on PLGA microparticles. Using this system, various 
effectors to pore healing are studied, such as pore geometry, PLGA structure, 
and environmental conditions. These studies allow for elucidation of the 
physical-mechanical nature of PLGA molecules during self-healing. 
Mathematical representations of the self-healing process are presented and 
existing polymer theory is modeled over the data. This chapter presents the 
underlying driving forces and limiting factors in self-healing, and is designed to 
empower researchers with better information as to how best utilize the 
technique in future work. 
Chapter 3 more directly capitalizes on self-healing by further exploring the 
Active Self-Encapsulation loading paradigm. PLGA microparticles are fabricated 
using Alhydrogel as a trapping agent. These microparticles are then evaluated 
in vitro for their ability to load and release stable vaccine antigens. Also 
included is an investigation into the various mechanisms of antigen release. 
This includes the evaluation of several clinically relevant antigens. 
Chapter 4 then takes these microparticles and encapsulates them in a 
microneedle patch. This patch is fully soluble, and designed to embed the 
loaded microparticles in the epidermis and dermis without the use of a 
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hypodermic needle. The mechanical strength of these microneedles is 
evaluated, with consideration towards how well and how deeply they are able to 
penetrate model skin tissue and deposit the microparticle payload. The patches 
are evaluated in vitro to determine if the controlled release capabilities of the 
microparticles have been affected. Lastly, the work concludes with an in vivo 
study of the capability of the microneedle patches to illicit a robust immune 
response in an animal model. 
It is the intention of Chapter 5 to summarize the important aspects of this 
work, and expound on potential future directions for these fields of research. 
Also included is an appendix of work collaboratively done to develop 
mathematical simulations of the self-healing process in PLGAs. 
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Chapter 2:  Healing Kinetics of Microneedle-formed Pores in PLGA Films 
2.1  Abstract 
 
The spontaneous healing of aqueous pores in poly(D,L-lactic-co-glycolic 
acid) (PLGA) drug delivery systems has been identified to play a key role in 
terminating the burst release of large molecules, and to provide a means for 
novel aqueous-based microencapsulation. To examine healing of PLGA, pores 
were created of defined size and depth on the surface of thin PLGA films by 
stamping with blunt-tip microneedles. Pore dimensions on the micron-scale 
were relevant to surface pores of common PLGA microspheres and could be 
easily monitored by light microscopy. Most pores healed reproducibly at 
temperatures above the glass-transition temperature (T
g
) of the films, with 
healing times decreasing sharply with increasing temperature according to 
Williams-Landel-Ferry (WLF) behavior. It is suggested that healing is driven by 
high surface tension in the films, and occurs through viscoelastic creep. 
Hydrated films healed at lower temperatures than dry films, consistent with a 
drop in T
g
 upon polymer hydration. Larger pores took longer to heal than 
smaller ones, while pores larger than 20 µm did not heal before significant 
polymer degradation occurred. Films of a less hydrophobic PLGA showed 
slower healing kinetics, attributed to a weaker surface tension driving force. 
Deeper pores showed signs of in-plane stress from spin-coating, and either 
ruptured or only partially healed when incubated wet and dry, respectively. 
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2.2  Introduction  
 
Poly(D,L-lactic-co-glycolic acids) (PLGAs) have been studied exclusively for 
controlled release devices for delivery of peptides, proteins, vaccine antigens, 
and even nucleic acids [1-6]. Despite their widespread use over more than four 
decades, a few fundamental physical-chemical properties of PLGAs having 
significant impact on their biomaterial performance have nonetheless remained 
elusive. An important example involves the spontaneous self-healing of pores 
in the polymer that are created during processing (e.g., microencapsulation and 
drying) and incubation. This phenomenon has been shown to play an important 
role in encapsulation and release of drugs and peptides [7-12], and could 
become of increased significance as the pharmaceutical pipeline becomes 
increasingly biologic, and greater precision and control is required of long-term 
controlled release devices. 
Passive healing in polymers is a known occurrence [13], and can reasonably 
be expected to occur and have similar relevance in numerous other biomaterials 
(e.g., poly(ethylene-co-vinyl) acetate and silicone rubber) commonly used for 
controlled release. For example, during previous evaluation of the release 
kinetics of a cyclic peptide (octreotide) from PLGA microspheres, the pores on 
the surface of the polymer were observed to slowly heal over a time-scale of 
hours in an aqueous medium [7]. The sealing of the surface pores was found to 
correspond to both the cessation of the initial burst release of peptide, and a 
sharp reduction in effective permeability of fluorescent markers capable of 
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entering the polymer matrix by pore-diffusion [7].  Similar behavior was also 
observed with bovine serum albumin (BSA) and dextran-loaded PLGA 
microspheres [14].  As the temperature was raised to a physiological 
temperature or above (i.e., above T
g
 of the hydrated polymer [15]), the initial 
burst release of both dextran and BSA dropped as polymer healing became 
more rapid. The use of pore-markers incubated outside the PLGA microspheres 
indicated that the healing of pores also occurred during the degradation phase 
of the polymer, suggesting a two-way valve mechanism of large molecule 
release [14].  Finally, spontaneous pore closing in water has recently been 
shown to facilitate encapsulation of macromolecules [8,9,13] without exposing 
them to the damaging organic solvents and sterilizing conditions used in 
traditional fabricating/loading methods [16-22].  
In order to better understand healing in PLGAs, developed here is a system 
that could be used to reproducibly evaluate the kinetics and mechanism of self-
healing in the polymer. To accomplish this, blunt microneedles capable of 
creating well-defined pore morphologies within the surface of PLGA films were 
exploited.  The purpose of this chapter is to describe this simple development 
and the key findings related to the kinetic behavior of PLGA self-healing of 
pores from a variety of pore sizes and depths. 
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2.3  Materials and Methods 
2.3.1  Materials 
 
Unless otherwise specified, the PLGA used was poly(D,L-lactic-co-glycolic 
acid) 50:50 with lauryl ester-terminated chains, inherent viscosity (i.v.) and 
weight-averaged molecular weight (Mw) of 0.61 dl/g in hexafluoroisopropanol 
(HFIP) at 25 °C and 55.3 kDa, respectively (Lactel Inc., Birmingham, AL). PLGA 
504H (50:50, carboxylic acid-terminated, Mw = 38-54 kDa, i.v. = .45-.60 dl/g) 
was also purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals 
were of analytical grade or higher. 
2.3.2  Fabrication of Blunt-tip Microneedle Stamps 
 
The general pattern of the stamps consisted of an array of square needles 
with inter-needle distance set at 10X needle width. Needles ranged between 1 
and 250 µm-wide squares, while the depth was set at 7 or 15 µm. The smaller 
arrays (≤ 5 µm) were surrounded by a larger square (1 mm thick) so the target 
area could be easily located. Three separate stamps were used; one with needles 
1, 2, 3, and 5 µm wide, 7 µm deep. The second contained needles 10, 20, 30, 
and 50 µm wide, also 7 µm deep. The final stamp had needles 50, 100, 150, and 
250 µm wide, but 15 µm deep. 
To form the microneedle stamps, a negative of the design was first drafted 
in L-edit (Tanner Research, Monrovia, CA), scaled up 5X from the final feature 
size. This was fractured into a series of squares and rectangles used to shoot 
the photomask reticle. The pattern was then exposed onto a 127 mm 
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photomask spin-coated with positive photoresist. After exposure, the 
photomask was developed in developer solution and the exposed areas were 
etched with chrome etchant before stripping away the remaining photoresist. 
The mask was then loaded into a stepper (GCA AS 200, Andover, MA), which 
scaled the feature size down by 5X, and the proper exposure times were 
determined incrementally. Silicon wafers were coated with 2.5 µm of positive 
photoresist (SPR 220 (3.0) series resist) by an ACS Cluster tool (SUSS MicroTech, 
Garching, Germany) and then etched (STS Pegasus 4, San Jose, CA) accordingly. 
The remaining photoresist was then stripped away and the wafers were 
characterized by contact profiling and SEM. Finally, the wafers were diced (ADT 
7100, Horsham, PA) into usable sizes before being glued to a plastic dowel for 
grip. 
2.3.3  Film Preparation and Stamping 
  
PLGA films were prepared by dissolving the PLGA in acetone (27% w/w) 
and then spin-coating the solution onto cover-glass slides using a G3-8 Spin 
Coater (Specialty Coating Systems Inc., Indianapolis, IN). The volume used was 
0.25 mL, coating time was 7 s, and the spin speeds were 1515 and 3200 rpm for 
ester- and acid-terminated polymers, respectively. The thicknesses of the films 
were determined by a microcaliper (Marathon, Ontario, Canada). Immediately 
after spin-coating, the microneedle stamps were gently pressed onto the film 
surface to create the indentation and then removed. Films were then dried for 
24 h in a fume-hood and 24 h under vacuum. Sample quality was ensured by 
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viewing each sample on a light microscope (Axiolab, Carl Zeiss, Oberkochen, 
Germany) with 5-40X magnification. Images were taken with a Canon Rebel EOS 
XSi equipped with a 2.5X phototube (Carl Zeiss) attached to the microscope. All 
samples were imaged prior to incubation for reference. Excess glass and 
polymer were cut away from the stamp area and the samples were stored at  
4 °C until further use.  
2.3.4  Film Incubation 
 
For incubation under aqueous conditions, the films were placed in plastic 
Petri dishes (5 cm diameter) and filled with 7 mL pre-warmed buffer solution 
before capping and allowed to stand during incubation (Precision, Thermo 
Scientific, Waltham, MA). The standard buffer was PBS (137 mM NaCl, 2.7 mM 
KCl, 10.1 mM Na
2
HPO
4
, 1.7 mM KH
2
PO
4
) + 0.02% Tween 80, pH 7.4 (PBST).  At 
predetermined times, the media were discarded, and the films were rinsed with 
distilled and deionized H
2
O to prevent salt formation. The films were then 
patted dry with tissue paper before immediate imaging. Three replicates were 
used for each time point and the samples were discarded after imaging. 
Films incubated without aqueous media were placed and capped in the 
same Petri dishes under ambient conditions before being placed in the 
incubator. At predetermined times, they were removed from the incubator, 
imaged quickly, and then returned for further incubation. 
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2.3.5  Thermal Analysis 
 
The amount of residual solvent was determined by thermogravimetic 
analysis (TGA) (Discovery, TA Instruments, New Castle, DE) as previously 
reported [22]. Briefly, 15-20 mg of sample were placed on platinum pans before 
equilibrating at 25 °C. The temperature was then ramped to 600 °C at 10 °/min. 
The solvent loss was determined from the mass lost between 25 °C and 150 °C, 
which is much lower than the temperature range over which significant mass 
loss of the polymer occurs.  
Glass-transition temperatures were determined by modulated differential 
scanning calorimeter (mDSC) (Discovery, TA Instruments, New Castle, DE). 
Approximately 10 mg of sample were crimped in aluminum pans. 
Temperatures were ramped between -20 °C and 150 °C (80 °C for hydrated films) 
at 3 °C/min, with a modulation amplitude of ± 1 °C/min (1.5 °C/min for 
hydrated films) and a period of 60 s. All samples were subjected to a 
heat/cool/heat cycle. The glass-transition temperatures of hydrated films were 
determined by soaking them in PBST at room-temperature for 1 h before 
patting dry, removing the glass substrate, and sealing with hermetic lids. The 
analysis was done using TA Trios software, and all experiments were 
performed in triplicate. 
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2.4  Results 
2.4.1  PLGA Films with Microneedle-stamped Pores 
 
Spin-coating under the given conditions produced films 26 ± 3 and  
24 ± 4 µm thick (mean ± SEM, n = 9) for ester- and acid-terminated films, 
respectively. The films began to dry rapidly after coating, so applying the 
microneedle stamps had to be done immediately. Each film was stamped 
several times in different locations, and the individual stamps were cut out 
after drying. Using the 1–5-µm stamp, only the 5-µm needles repeatedly 
produced usable pores. In some instances, and particularly with larger pores, a 
ridge appeared around the pores as a result of in-plane compressive stresses. 
This appears as a black ring in some light microscope images. 
After drying, the films appeared generally uniform and transparent with a 
modest level of roughness (Fig 2-1). No significant differences were observed 
between the two PLGAs used, although different spin-speeds were required to 
achieve similar thicknesses. Pores ranged between 5 and 250 µm in width. The 
5-µm-wide, 7-µm-deep pores were used for all experiments except when the 
effect of pore size was evaluated, as described below. The amounts of residual 
solvent and glass-transition temperatures are presented in Table 1. 
2.4.2  Effect of Temperature on Healing Time in PBST 
 
When PLGA films were incubated in PBST at temperatures of 43 °C and 
above, the pores slowly healed until the surface became uniform and no 
evidence of the pores could be observed by light or scanning electron 
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microscopy (SEM). For example, in Fig 2-2A films are displayed at different 
stages of the healing process under aqueous conditions. The morphology of the 
pores suggest that healing occurs both from the edges in and from the bottom 
up, as the initially square pores quickly became circular, but the outline of the 
pore could be observed throughout healing. The film around the pores became 
rougher as the incubation continued, likely due to hydration of the film or from 
buffer solution trapped between the film and the glass substrate after drying. 
As the incubation temperature increased, the healing times decreased, as 
shown in Fig 2-3A. 
When films were incubated at 37 °C, they became an opaque milky-white, 
and SEM was required to evaluate pore morphology. Here, the early stages of 
healing could be observed (rounding out of pores and some loss of definition) 
but full healing did not occur after two weeks. Results were similar when 
incubated at 25 °C for one week, although the films remained translucent and 
any change to pore morphology was minimal. Finally, when incubated at 5 °C 
the films’ morphology did not change, and remained smooth during a one-week 
incubation, suggesting only minimal hydration of the glassy polymer 
(supplementary information). 
2.4.3  Effect of Temperature on Dry Healing 
 
When the films were incubated dry, the required healing times jumped 
significantly, and the minimal required temperature to observe healing at 
reasonable time scales rose to 50 °C. Similar to the behavior of wet films, 
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further increases in temperature reduced healing time, as shown in Fig 2-3B. 
The pores also behaved in a similar fashion, becoming less well defined over 
time. In contrast to the wet films, the parts of the films surrounding the pores 
remained smooth throughout incubation (Fig 2-2B). 
2.4.4  Healing Kinetics of Carboxylic Acid-terminated PLGA 
 
When the more hydrophilic, carboxylic acid-terminated PLGA 504H was 
used in healing studies, the rate of healing slowed considerably. When 
incubated in PBST at 50 °C, healing was not complete after three days, at which 
point the polymer was severely degraded. Partially-degraded films were imaged 
on SEM, and unhealed pores were still clearly visible with only minor 
morphology changes (supplementary information). When incubated dry, healing 
proceeded similar to that of dry-healed ester-terminated PLGA films, but 
required higher temperatures. For example, the lowest temperature used was 
55 °C, which took over 5 days before complete healing was observed  
(see Fig 2-4). 
2.4.5  Fitting Williams-Landel-Ferry (WLF) and Arrhenius Equations to PLGA 
Healing Data 
 
In order to test if polymer healing was dependent on the viscoelastic 
properties of the polymer, as would be expected if healing occurs by material 
flow to minimize surface energy, the healing times of 5-µm pores in both dry 
(ester- and acid-terminated polymers) and aqueous (ester-terminated only) 
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conditions were fit by the Williams-Landel-Ferry equation for time-temperature 
superposition: 
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where t and T are time and temperature, respectively; t
o
 is the reference time at 
the reference temperature T
o
, and C
1
 and C
2
 are constants. When T
g
 is used as 
the reference temperature T
o
, then the constants C
1
 and C
2
 become universal 
values of 17.4 and 51.6 K, respectively [23]. The T
g
 recorded during the first 
heating cycle of mDSC were used (see Table 1), as this best simulates 
experimental conditions. Data were independently fit using non-linear 
regression to determine t
o
 for all data sets. As shown in Fig 2-4, the WLF 
equation could be adequately fit to the data (r2 > .951), yielding t
o
 = 1.78∙106 h, 
4.35∙106 h, and 2.4∙108 h for lauryl ester-terminated dry and wet films, and 
acid-end group dry films, respectively.  
An approximate mechanics analysis of healing indicated that healing times 
should follow an Arrhenius rate law of the form: 
                                       RTQAet /                                  (2) 
 Therefore, to determine the activation energy for the healing process, 
healing data were individually plotted on an Arrhenius plot (ln(t) vs. 1/T)  
(Fig 2-4 inset). The activation energy (Q) was determined by dividing the slope 
of the line by the gas constant, R. The observed values of Q were 288 kJ/mol  
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(r2 = .985), 193 kJ/mol (r2 = .973), and 240 kJ/mol (r2 = .991) for lauryl ester-
terminated dry and wet films, and acid-end group dry films, respectively. 
2.4.6  Effects of Pore Width 
 
Pores could be made using microneedles of 5, 10, 20, 30, and 50 µm width, 
all at a depth of 7 µm. When incubated in PBST, the healing time was found to 
increase with pore width for the 5, 10, and 20 µm pores (Fig 2-5). Pores of 30 
and 50-µm size displayed the beginning signs of pore closing, (i.e., pores had 
become circular, and were becoming less distinct – consistent with healing in 
the smaller pores). However, complete healing was not observed by 48 h  
(at 50 °C), at which time the films were so significantly damaged by degradation 
that further observations were not possible (Fig 2-6A). Had a thicker film or 
non-degradable polymer been used, it is likely that these pores would have 
healed eventually. 
2.4.7  Effects of Pore Depth 
 
A set of pores with a depth of 15 µm, which extended them more than 
halfway through the 26 µm film, were also made with widths of 50, 100, 150, 
and 250 µm. When incubated in aqueous conditions at 50 °C, these pores 
tended to rupture rather than heal (Fig 2-6B). That is, the pores went from 
initially being a dent on the film surface, to a through-hole that extended to the 
glass substrate. The polymer at the bottom of the pores tore away from the 
glass, and the pores grew up to 300% in diameter while becoming more circular. 
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The larger pores tended to rupture less often than the smaller ones, although 
none demonstrated healing during the times studied (up to 48 h). 
When the study was conducted under dry conditions at 60 °C, the 
rupturing phenomenon was not typically observed. These pores showed some 
signs of the onset of healing, but did not heal fully on relevant timescale  
(< 2 wks). The pores had clearly become smaller and less distinct, but never 
fully disappeared. On rare occasions, some of the pores did rupture, but did 
not grow as they had in the aqueous experiment. 
2.5  Discussion 
 
The model system of using PLGA films stamped with a microneedle array 
proved to be a reliable system for reproducibly measuring pore-healing. Pores 
could be made of controlled width and depth, and could be individually 
monitored by light microscopy or occasionally SEM. This method did 
demonstrate difficulties creating pores smaller than 5 µm wide, which may 
have been because the polymer solution was able to relax back into these small 
pores, or because the 10X inter-needle distance was not sufficient in these 
instances. An alternative currently being explored for making smaller surface 
pores is physical indentation by the tip of an Atomic Force Microscope (AFM), 
similar to a previously reported study [24]. In addition, Axelsson et al. used 
ZnCl
2
 as a pore forming excipient in PLGA films, but this method produced 
pores with great polydispersity and it was not possible to have precise control 
over the number or spacing of the pores [25]. 
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After drying, the films contained a slightly elevated level of residual 
solvent, but this was expected since drying at elevated temperature (annealing) 
could not be done, as it would also begin to heal the pores. The glass-transition 
temperatures recorded are in reasonable agreement with previously reported 
values, and a drop in T
g
 for the hydrated films is consistent with the 
plasticization effect of water on the polymer [15]. The change in T
g
 in the dry 
films compared to the raw polymer is likely due to residual solvent, which is 
partially released during the first heating cycle, and leads to the higher T
g
 seen 
in the second heating cycle. Since the acid-end capped films had more residual 
solvent, the T
g
 increases more dramatically between cycles. While the first T
g
 
was used for analysis, the true T
g
 likely changes between the two reported 
values during the course of the experiment as more solvent evaporates or more 
water enters the polymer matrix [25].  
It is known that mid-to-high Mw PLGA films have a high interfacial tension, 
particularly in aqueous environments. This is frequently demonstrated by low 
wettability and/or a high water droplet contact angle, and is the result of a 
combination of van der Waals’ interactions, hydrophobic interactions, and 
preference of the methyl side chains of lactic acid units to orientate to the 
polymer-air interface [25-28]. While lauryl ester-terminated PLGAs are 
particularly hydrophobic, carboxylic acid-capped PLGAs are less so. This results 
in weaker hydrophobic interactions, and lower surface stresses as evident by 
more acute water-droplet contact angles [29]. While these effects are 
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particularly pronounced in aqueous environments, they also affect dry healing 
under ambient humidity, and weaken the tension at the polymer-air interface. 
The results presented here are consistent with a model for pore healing 
driven by surface tension and controlled by the rate of deformation of the 
polymer. In the absence of any other stresses, the surface tension and local 
curvature set up a stress field that drives flow of the polymer to reduce the 
surface area and, hence, heal the pores. A simple special case that serves to 
illustrate the physics of the phenomenon is the healing of a spherical pore in a 
linear viscous material.  The von Mises effective stress (~ ) at a distance r from 
the surface of the sphere is given by 
                                   32 /3~ ra       (3) 
where γ  is the surface tension of the material, and a is the radius of the pore.  
Assuming that the material obeys a Levy-Mises flow rule with a linear 
relationship between the effective stress and effective strain rate ( ~ ): 
                                  3/~~        (4) 
where   is the viscosity. Assuming a single thermally-activated mechanism for 
flow, with an activation energy Q, the viscosity is of the form 
                            RTQo /exp       (5) 
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where o is a material constant, R is the molar gas constant, and T is the 
absolute temperature.  These equations can be used to show that the healing 
time (t) for a spherical pore is given by 
                           //exp2 RTQat oo      (6) 
where a
o
 is the initial pore radius. 
 While this model has an oversimplified geometry and, probably, an 
oversimplified constitutive law, it does provide a good connection to many of 
the experimental observations.  Firstly, it should be noted that the transition 
from the square pore to the rounded shape is a classic sign of a surface-tension 
driven phenomenon.  The stresses that drive flow are inversely dependent on 
the local radius of curvature (as in Eqn. (3)), so there is a very large driving 
force for the sharp corners of a square to be rounded out, and the pore to take 
up a circular shape to minimize surface energy. Secondly, Eqn. (6) shows that 
the healing time is proportional to the initial pore size.  A linear relationship 
would be a direct consequence of a linear constitutive law; non-linear materials 
would exhibit a non-linearity in this relationship. While there are only three 
data points in Fig 2-5, the data are in general agreement with what would be 
expected in this type of phenomenon. In ester-terminated PLGA, it is noted that 
all the pores 7 µm in depth began to heal when incubated above T
g
 in aqueous 
conditions, but not all pores managed to close completely before significant 
degradation took place. The potential of an upper size limit on healing has 
great implications for PLGA devices used in controlled release; since the healing 
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phenomenon is now gaining interest as a possible encapsulation strategy [13], it 
suggests that particularly large pores may not heal before a degradation phase 
begins. Any unhealed pores would contribute significantly to burst release 
upon incubation in release media. This may limit or add additional 
considerations to the types of PLGA devices that are considered for this loading 
paradigm. Lastly, Eqn. (6) suggests that an Arrhenius plot will give the 
activation energy for the flow process. Fig 2-4 shows such a plot, indicating 
activation energies of roughly 288 kJ/mol, and 193 kJ/mol for the ester-
terminated polymer in dry and wet conditions, respectively, and 240 kJ/mol for 
dry acid-terminated PLGA – values within the somewhat wide range of apparent 
activation energies reported for polymer flow and relaxation [30-32]. A lower 
activation energy for the hydrated polymer is expected, as water acts as a 
lubricant to polymer flow. Also, despite healing slower, a lower activation 
energy for acid-capped PLGA compared to the ester-terminated PLGA is 
expected. The former has a lower Mw and a further depressed T
g
, so the 
polymer chains have more freedom to move, and can do so more readily. 
However, the observed healing kinetics are slower in acid-capped PLGA due to a 
lower overall driving force. This is an important distinction with regards to self-
healing in PLGA microspheres, as choosing a more mobile polymer may not 
always promote faster self-healing unless the effect on other parameters, 
notably surface tension, are considered as well. 
Data from Figures 2-2 and 2-3, along with the T
g
 information, indicate that 
healing of the microneedle-stamped pores takes place in a reasonable time-
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frame when the polymer is in the rubbery state above the T
g
, but not in the 
glassy state below it. The time-temperature shift associated with the WLF 
equation for polymers is another manifestation of a thermally-activated 
process, with significant mobility being associated with temperatures above the 
glass-transition temperature. Driven by the stress of surface tension, this 
enhanced mobility allows viscoelastic flow of the polymer to heal defects. This 
flow in response to surface tension could be considered a form of creep that 
occurs when T > T
g
. Although healing was not observed in aqueous conditions 
at 37 °C, it is clear from previous research that healing at this temperature is 
possible [13]. The WLF equation predicts that pores would have healed if 
experiments were carried out longer (35 days for healing in PBST at  
37 °C, 65 days for dry healing at 46 °C). Microspheres typically have smaller 
pores, and may have greater surface tension caused by a very different 
manufacturing process, or a lower T
g
 due to the inclusion of excipients, thus 
allowing them to heal faster at 37 °C than is predicted here. Additionally, the 
reason pores in PLGA 504H did not heal when exposed to aqueous conditions is 
likely two-fold. First, this polymer degrades much faster than ester-capped 
PLGA, limiting the window over which healing can be seen. Second, the lower 
hydrophobicity caused by the presence of the carboxylic acid severely weakens 
the surface tension driving force. 
 The behavior of 15-µm deep pores when incubated under aqueous 
conditions was particularly intriguing. These pores did not heal, and in fact 
grew in size significantly and caused damage to the film. It is possible that this 
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occurred because the films were spin-coated to a glass substrate, and this 
allowed an in-plane stress to develop, as has been previously reported [33].  
Therefore, the rupturing phenomenon might not be expected to extend to free-
standing PLGA microspheres. Nonetheless, whether a pore will heal or extend 
and rupture depends on a competition between elastic strain energy and 
surface energy. The relative importance of these two terms is measured by the 
dimensionless group σa
o
/γE [34], where E is the appropriate elastic modulus of 
the polymer, and σ is the normal stress at the tip of the pore. If the value of 
this group is small, the problem is dominated by surface tension, and the pore 
is expected to heal.  Conversely, if the value of this group is large, the problem 
is dominated by the elastic energy term and rupture is favored. It is possible 
that rupturing occurred more commonly under wet conditions because of 
moisture uptake by the polymer leading to an enhanced stress. It should be 
noted that swelling caused by moisture uptake for microparticles and other 
PLGA devices might cause the pores to open initially [7], depending on the 
relative time scales for moisture absorption and healing.  Whether the pores 
would eventually heal or not would likely depend on the nature of any 
geometrical constraint (similar as that provided by the glass substrate) that 
might result in the evolution of elastic stresses.  
2.6  Conclusion 
 
Healing of PLGA devices is an important phenomenon with strong 
implications for affecting release kinetics and providing an avenue for aqueous-
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based encapsulation of large molecules. The microneedle-stamped films used 
here are a simple way to study this phenomenon in a controlled pore geometry. 
This system allowed the healing behavior of different PLGAs exposed to various 
conditions to be identified, and the data was adequately described by universal 
WLF and Arrhenius behavior. Self-healing was consistent with a surface tension 
driven process, causing creep when the polymer was above the T
g
 and chain 
motion via viscoelastic flow was possible. In the future, this approach may 
allow more quantitative assessment of healing phenomenon in PLGA and other 
biomaterials. 
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Figure 2-1: Representative light micrographs of PLGA films with various surface pores created by blunt-
tip microneedle stamps. 7 µm deep and A) 5 µm wide, B) 10 µm wide, C) 50 µm wide, E) 30 µm wide; 
and 15 µm deep and D) 50 µm wide, and F) 250 µm wide. 
 
 
 
 
 
 
 
Polymer 
End-cap 
Residual 
Solvent (%) 
Raw Polymer Tg (°C) Dried Film Tg (°C) Hydrated Film Tg (°C) 
First Heat Second Heat First Heat Second Heat First Heat Second Heat 
Lauryl Ester 1.7 ± 0.1 42.7 ± 0.3 44.7 ± 0.2 35.4 ± 0.3 40.7 ± 0.3 23.4 ± 0.4 24.0 ± 0.3 
Carboxylic Acid 3.6 ± 0.4 51.5 ± 0.6 48.4 ± 0.1 26.4 ± 0.4 45.1 ± 1.8 18.7 ± 0.5 18.5 ± 0.6 
 
Table 2-1: Residual solvent and glass-transition temperature measurements as determined by TGA and 
mDSC, respectively. The Tg from the first heating cycle was used in further calculations. n = 3, ± SEM. 
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Figure 2-2: Healing of surface pores in A) PBST and B) air after; 1) 0 h, 2) 2 h, 3) 4 h, 4) 6 h, and 5) 8 h. 
Scale = 50 µm. 
 
 
 
 
 
 
 
 
 
Figure 2-3: Effect of temperature on healing time of 5-µm pores on PLGA films incubated in A) PBST, 
and B) air (no hydration). n = 3, ± range. 
A B 
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Figure 2-4: WLF describes healing time of 5-µm pores in lauryl ester-terminated PLGA incubated in 
PBST (▲) or dry (■) conditions, and carboxylic acid-terminated PLGA incubated dry (●). Data from Figure 
2-3 was fitted by non-linear regression to WLF equation using To = Tg, C1 = 17.4 K, and C2 = 51.6 K. 
r
2 
= .951 (ester-terminated dry), .993 (ester-terminated in PBST), and .981 (acid-terminated dry). 
Inset: Arrhenius plot of healing data. Resulting activation energies are 288 kJ/mol for dry incubation  
(r
2
 = .985), 193 kJ/mol for incubation in PBST (r
2
 = .973), and 240 kJ/mol for acid-capped PLGA 
incubated dry (r
2
 = .991).   
 
 
 
 
Figure 2-5: Healing time as a function of pore width under hydrated conditions at 50 °C. All pores were  
7 µm deep. n = 3, ± range.  
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Figure 2-6: Light micrographs of microneedle-stamped PLGA pores (50 µm wide) after incubation.  
A) 7 µm deep. B) 15 µm deep. 1) before incubation. 2) after incubation in PBST. 3) after incubation in air.  
Scale = 50 µm. 
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2.9  Supplementary Information 
2.9.1  Measurement of Surface Tension 
 
The surface tensions of the PLGA films were determined by placing a drop 
of milliQ water on the films and using a goniometer to measure the polymer-
water contact angle.  Contact angles for each film were measured in three 
distinct locations, and a minimum of two samples were used for each set of 
conditions.  The contact angles were used to calculate the tension, γ, following 
Berthelot’s combining rule [35]. 
                  4/cos1 2 lv       (7) 
 where θ is the contact angle, and γ
 lv
 is the surface tension of water.  
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Supplementary Figure 2-2: Interfacial tension of PLGA films decreases with annealing time when 
incubated at various temperatures. n = 6, ± SEM. 
 
 
A B
C D 
E 
Supplementary Figure 2-1: Unhealed 5-µm pores after incubation in PBST. A) 1 week at 25 °C, B) 1 week 
at 5 °C, C) 2 weeks at 37 °C, D) SEM image of film in C), provided due to obscurities on light micrograph, and 
E) SEM image of stamped acid-terminated PLGA film after incubation in PBST at 50 °C for 3 days, with 
unhealed square pores marked by arrows. Scale = 50 µm. 
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Chapter 3: Active Self-Encapsulating PLGA Microparticles for Controlled 
Release of Vaccine Antigens 
3.1 Abstract 
 
Long-acting controlled release systems are an advantageous method of 
delivering biomacromolecules (e.g., protein antigens/vaccines) as they reduce 
injection frequency, thus increasing patient compliance and overall coverage. 
However, the conventional controlled release strategy of encapsulating 
therapeutic agents into microparticles of poly(lactic-co-glycolic acid) (PLGA) is 
not well suited to proteins, as proteins are typically damaged by the 
encapsulation process. Presented here is the development of PLGA 
microparticles that can be remotely loaded from an aqueous protein solution – 
removing the protein from the emulsion procedure. This process, termed Active 
Self-Encapsulation, relies on a trapping agent to draw the protein into the 
microparticles where it is encapsulated by the healing of surface pores on the 
microparticles. By using the common vaccine adjuvant Alhydrogel as the 
trapping agent, a variety of different antigens were successfully encapsulated in 
the same microparticle formulation. This yielded high and reproducible antigen 
loading (1.6% w/w for the model antigen Ovalbumin), with encapsulation 
efficiencies over 90%. In vitro, these microparticles demonstrated biphasic 
controlled release of antigen over greater than one month. Initially, soluble 
antigen was released as antigen desorbed from Alhydrogel and diffused out of 
59 
 
the microparticles. Later, the microparticles physically degraded to release 
particulate antigen complexed to Alhydrogel. This technique is well suited to a 
variety of proteins and thus disease states. It could also offer the option for 
point-of-care compounding, where a hospital/pharmacy could maintain a stock 
of microparticles to be loaded pro re nata based on patient needs.  
3.2  Introduction 
 
Most modern vaccines are given on a schedule. These consist of a series of 
immunizations (shots) spread out over weeks to years (1). These schedules are 
necessary to fully develop protective immunity and/or maintain immunity that 
may fade over time. This necessity is largely due to a collective movement away 
from attenuated vaccines towards inactivated or purified options (2). While 
inactivated and purified vaccines are safer, they do not generate powerful 
immune responses, thus requiring more exposures to develop protective 
immunity. While such vaccines contain adjuvants that may increase the 
immune response, they do not develop any sort of infection. This allows them 
to be rapidly cleared. In general, if an insult can be rapidly overpowered, 
immunological memory does not develop as it is not required (2,3). While these 
scheduled doses are effective, they also present several caveats. First, they 
require multiple trips to a healthcare provider to receive the doses. In 
developed nations, this may only be an inconvenience to otherwise busy lives. 
In developing nations, however, this may require long travel times or not be 
feasible. More so, if an individual skips or misses a dose, they may not have the 
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protective immunity they think they do. Overall, vaccine schedules add cost, 
time, and the possibility of error to an otherwise critical piece of public health.  
To overcome these challenges, researchers are developing single 
administration vaccines (4-7) that can be administered once and offer long-
lasting protection. Most of these formulations contain some mechanism of 
controlled release where a depot holds or hides the antigen and slowly presents 
it to the immune system over time. These can be pulsatile to mimic the prime-
booster paradigm already used (6,8,9), or continuous to better represent how 
an infection would naturally develop (10,11). Single-administration vaccines 
have the obvious advantage of only requiring a single administration to provide 
protective immunity – removing the possibility of missing a necessary booster 
dose. This makes the vaccine more convenient, and could help reduce cost and 
improve vaccine coverage world-wide. However, new research has shown that 
the kinetics of antigen presentation to the immune system may also determine 
the strength of response, and in this way continuous controlled release 
vaccines may be advantageous over repeat injections (12). For example, when a 
fixed dose of a meningitis antigen was administered to mice either as a single 
bolus dose, or spread out over several says, the “continuous” administration 
produced a more robust immune response. More so, an exponential increase in 
antigen generated the strongest response. The authors suspect that since this 
exponential increase best mimics a growing infection, and that is how evolution 
has told the immune system to expect a pathogen, the body is best prepared to 
provide a response (12).  
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While there are many methods researchers use to create controlled antigen 
release, a common practice is the encapsulation of antigens in a bioerodable 
polymer. Perhaps the most common of these polymers are  
poly(lactic-co-glycolic acids) (PLGAs), which are already used in a litany of FDA-
approved devices for controlled release (13,14). Several reviews are available 
explaining the advantages and utility of such devices, which are too numerous 
to detail here (14-16). Typically, however, PLGAs are made into microparticles – 
small spheres ranging between roughly 1 and 100 µm in diameter. These 
microparticles contain the therapeutic mixed in somehow, and slowly release it 
through a variety of mechanisms (14,15). While PLGA microparticles have had 
great success encapsulating and releasing small molecule-based drugs, the 
technology has historically not translated well to large biomacromolecules such 
as protein antigens(13). The shear stresses, solvent interfaces, lyophilization, 
and often γ-irradiation used in the fabrication and sterilization of PLGA 
microparticles are too damaging to sensitive proteins (17-20). In one such 
study, after encapsulating Tetanus Toxoid (TT) protein inside PLGA 
microparticles, approximately 75% of the antigen was damaged as a result of 
the fabrication process (19). 
To overcome the challenges of encapsulating proteins in PLGA 
microparticles, a new protein-loading paradigm has been set forth. Termed self-
healing encapsulation, this strategy separates the fabrication of PLGA 
microparticles from the act of protein loading (19,21-23). That is, the 
microparticles are made without protein but with other excipients, and are 
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loaded remotely from an aqueous protein solution as a later step. This system 
relies on the dynamic pore behavior of PLGA microparticles (24). In brief, when 
microparticles are made via a w/o/w double emulsion, the inner-water phase 
forms a network of pores inside the hardened microparticles. If this inner-water 
phase contains more dissolved solutes than the outer-water phase, an osmotic 
imbalance exists, and the surface of the microparticle will yield, creating 
surface pores. Because proteins cannot penetrate the polymer, aqueous 
diffusion through these pore networks is typically the rate-limiting step early in 
the release, eventually switching to polymer erosion-limited processes later on. 
It was recently noticed that these pores are dynamic – closing and opening 
during in vitro release studies. Previous work shows this is a viscoelastic 
phenomenon driven by surface tension and resisted by viscosity (24,25). 
Furthermore, the pore morphology appears to correlate with release. When the 
pores are open, release is rapid, and when closed release is slow or non-existent 
(26). So, self-healing encapsulation utilizes the dynamic nature of these pores 
as a means of protein entrapment inside the microparticles. After fabricating 
porous microparticles, they are soaked in an aqueous protein solution. The 
proteins diffuse into the pores, and heat is applied to heal/close the pores, 
trapping the protein inside and effectively loading the microparticles. Because 
no external stresses other than mild heat are applied, the encapsulated protein 
is more stable than in conventional encapsulation methods (19). Also, by 
loading microparticles after they have been fabricated, it allows early 
formulation optimization to be performed without wasting protein and ensures 
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that only microparticles in the desired size range are loaded. Lastly, when these 
microparticles are then taken to release, the pores slowly reform and the 
polymer degrades, releasing the protein. 
While this method is effective, it suffers from low encapsulation 
efficiencies. Also, to obtain high loading, very high concentrations of proteins 
are required. To improve upon this technique, Active Self-Encapsulation (ASE) 
was developed (19,21,23). Here, a trapping agent is added to draw the protein 
into the microparticles and sequester it there while the pores are healed. A 
schematic of this technique is outlined in Fig 3-1. The choice of trapping agent 
varies based on the protein to be encapsulated and the disease state being 
treated, but in the case of vaccine antigens, metal-based adjuvants are a 
promising choice as they are already used in approved vaccines and can 
effectively bind to many different antigens. 
Presented here is a continuation of previous research utilizing the ASE 
loading strategy. PLGA microparticles are fabricated without protein present – 
containing only Alhydrogel, a common vaccine adjuvant, and trehalose as a 
stabilizing and pore-forming excipient. Shown here, however, is that these 
microparticles prove capable of loading a variety of model and clinical antigens 
without any changes to the microparticle formulation. The release behavior of 
these microparticles is also studied in greater detail. This vaccine delivery 
system could offer many advantages. Consider for example a healthcare center 
in a developing nation. It would now only need to store bulk quantities of 
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unloaded microparticles, which are considerably more shelf-stable than 
microparticles containing protein. These microparticles could then be loaded 
with different antigens on a case-by-case basis and offer full protective 
immunity from a single administration. Furthermore, this chapter lays the 
groundwork for the following chapter (Chapter 4), where these microparticles 
will be incorporated into microneedle designs for intradermal administration. 
3.3  Materials & Methods 
3.3.1  Materials 
 
PLGA 50:50 (i.v. = 0.60 dL/g, Mw ≈ 55.4 kDa, ester terminated) was 
purchased from Lactel. Poly(vinyl alcohol) (PVA) (80% hydrolyzed,  
Mw = 9-10 kDa) and Ovalbumin (OVA) was purchased from Sigma Aldrich. 
Recombinant Hepatitis B surface antigen (rHBsAg) was from Arista Biologics. 
Recombinant protective antigen (rPA) was purchased from List Laboratories.  
F1-V antigen was from NIH BEI Resources. Alhydrogel 2% was from Invivogen. 
OVA-AlexaFluor 488 and OVA-AlexaFluor 647 was from Life Technologies. All 
chemicals were analytical grade or better. 
3.3.2  Preparation of Active Self-Encapsulating PLGA Microparticles 
 
Water-in-oil-in-water (w/o/w) double-emulsion porous PLGA microparticles 
were prepared via solvent evaporation adapting on methods previously 
reported (19). 350 mg PLGA was dissolved in 1 mL dichloromethane. The inner-
water phase was prepared by concentrating Alhydrogel to 6.35% via 
centrifugation and removal of excess solution, then 8% w/v trehalose was added 
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and the slurry was mixed. 0.2 mL of the inner-water phase was added to 1 mL 
of the dissolved polymer phase, then homogenized for 1 minute at 17k rpm on 
a Tempest I.Q.2 Sentry Microprocessor. 2 mL of a 5% (w/v) PVA solution was 
then dumped into the PLGA and vortexed for 50 s. Lastly, the w/o/w emulsion 
was poured into 100 mL of a 0.5% (w/v) PVA solution and hardened under rapid 
stirring for 3 hours. The resulting microparticles were passed through a 60 µm 
and 10 µm sieve in series and washed with ddH
2
O to remove excess PVA. The 
microparticles were then centrifuged (200 g, 5 min) to remove excess liquid, 
frozen by submersion in LN
2
, and lyophilized for 48 h. 
3.3.3  Scanning Electron Microscopy 
 
Surface morphology of PLGA microparticles was evaluated by mounting 
dry microparticles on double-sided carbon tape and imaging on a FEI Quanta 
3D scanning electron microscope (SEM) operated in low vacuum mode at 
voltages of 5 or 10 kV. Images were captured on EDAX® software. 
3.3.4  Microsphere Size Analysis  
 
In addition to verification via SEM, microparticle size and polydispersity 
was evaluated on a Malvern Mastersizer 2000. Roughly 10 mg of hydrated 
microspheres were resuspended in ddH
2
O and added to the chamber filled with 
ddH
2
O. The suspension was stirred at 3000 rpm, and 10 measurements were 
performed per sample at a sampling time of 15 s. Multiple records were taken 
at obscuration levels between 3 and 15% to ensure measurement stability and 
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that settling was not occurring. The dispersant and particle RI was 1.33 and 
1.59, respectively.   
3.3.5  Loading and Encapsulation Efficiency of Vaccine Antigens in ASE 
Microparticles 
 
Active Self-Encapsulation of model and clinical vaccine antigens was 
modified from previously reported methods (19). Flocculated antigens (OVA & 
rPA) were resuspended at a stock concentration of 1 mg/mL in 10 mM MOPS 
buffer, pH 7.4. F1-V and rHBsAg were first buffer exchanged from PBS to MOPS 
using Microcon centrifugal filter devices with a 10K MWCO and following the 
provided guidelines, then brought to a 1 mg/mL stock in MOPS. Unless 
otherwise specified, 0.5 mL of 1 mg/mL antigen solution was added to 20 mg 
microparticles in a low protein-binding 0.5 mL microcentrifuge tube. The tube 
was protected from light and rotated for 2 d at 4 °C, 1 d at room temperature, 
and 2 d at 42 °C. After incubation the suspension was centrifuged for 5 min at 
6010 rcf and the supernatant was removed and saved for analysis. The 
microparticle pellet was transferred to a 2 mL low protein-binding 
microcentrifuge tube and washed 3X with MOPS. Loading and encapsulation 
efficiencies (EE%) were determined using the following formulas using the lost 
mass of antigen from the loading solution compared against positive controls. 
% w/w loading: 
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑏𝑦 𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
 × 100  
EE%: 
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑏𝑦 𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑖𝑛 𝑡ℎ𝑒 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
 × 100 
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3.3.6  Adsorption and Release of Antigens to and from Alhydrogel 
 
To evaluate various antigens’ abilities to adsorb and desorb from 
Alhydrogel, antigens were diluted to 400 µg/mL in 10 mM MOPS buffer. 
Alhydrogel was similarly diluted to 200 µg/mL (100 µg/mL for rHBsAg), and  
1 mL each of antigen and Alhydrogel solutions were mixed and sent through a 
similar loading gamut as mentioned above. The samples were then spun down, 
the supernatant was collected and analyzed by HPLC and/or UPLC, and the 
samples were washed 3X with 1 mL MOPS before being sent to release at 37 °C 
in 1 mL PBST while shaking at 240 rpm. 
3.3.7  Size Exclusion Chromatography of Antigens 
 
Unless otherwise stated, antigen concentration was determined by size-
exclusion chromatography (SEC) using either high or ultra performance liquid 
chromatography (HPLC/UPLC). In either case, the mobile phase consisted of 
PBS, pH 7.4, flowed at 1 mL/min (HPLC) or 0.4 mL/min (UPLC). Injection 
volumes were 50 or 10 µL for HPLC and UPLC, respectively. All samples were 
filtered through 0.45 µm filters prior to injection. A TSKgel G3000SWxl column 
was used for HPLC and an Acquity BEH SEC (4.6 X 150 mm) column was used 
for UPLC. UV detection was done at 215 nm. All samples were carried out in 
triplicate or greater. 
3.3.8  Total Nitrogen Analysis 
 
Total protein content was extrapolated from total nitrogen content using a 
modified automated Dumas technique (27). While this method was also used to 
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confirm microparticle loading, its primary utility was to determine the amount 
of protein remaining in a sample at various stages of release. Microparticle 
pellets were washed 3X with ddH
2
O, then freeze-dried. 1 – 4 mg of 
microparticles were then massed into tin pans, which were crimped to remove 
excess air. Samples were run on a Leco TrueSpec® Micro CHN. The instrument 
was first blanked without samples to establish atmospheric baselines. Carbon, 
hydrogen, and nitrogen standards were then set in the anticipated range of 
nitrogen mass using USP grade EDTA. Lyophilized antigen standards were run 
to verify the percent nitrogen in the protein and set a Protein Factor. 
Microparticle samples were then dropped into the combustion chamber at 1050 
°C, which converts all nitrogen to nitrogen gas, which is then quantified by a 
thermal conductivity cell. Protein content was determined by multiplying the 
nitrogen mass by the protein factor after first subtracting the nitrogen mass 
from negative controls (unloaded microparticles). Percent protein could then be 
determined by dividing protein mass by total sample mass. 
3.3.7  Modulated Differential Scanning Calorimetry 
 
Glass-transition temperatures (T
g
) were determined by modulated 
differential scanning calorimetry (mDSC). For dry T
g
, approximately 5 mg of 
lyophilized microparticles were crimped in aluminum pans with a non-hermetic 
lid. For hydrated T
g
, samples were sent through the loading gamut mentioned 
in Section 3.3.5 (with or without antigen present), then excess solution was 
removed to create a slurry which was then transferred to aluminum pans 
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crimped with a hermetic lid. Temperatures were ramped between 5 °C and  
80 °C at 3 °C/min, with a modulation amplitude of ± 1.0 °C/min and a period of 
60 s. All samples were subjected to a heat/cool/heat cycle and the 2nd T
g
 was 
reported as the midpoint of the exothermic event. The analysis was done using 
TA Trios software, and all experiments were performed in triplicate. 
3.3.8  In vitro Release of Soluble Antigen from Microparticles 
 
After loading and washing, microparticles were resuspended in 1 mL PBST 
(PBS + 0.02% Tween 80), pH 7.4. The suspension was then shaken at 240 rpm at 
37 °C while protected from light. At each timepoint (1, 3, 7 days and weekly 
thereafter), the microparticles were centrifuged 5 mins at 6010 rcf and the full 
release media was removed for SEC analysis and replaced with fresh PBST. 
3.3.9  Distribution of Encapsulated Antigen within Microparticles and 
Evaluation of Particulate Release fraction 
 
To visualize the distribution of antigen inside the microparticles after 
encapsulation, microparticles were loaded using an Ovalbumin-Alexa Fluor 647 
conjugate (OVA-AF647) similar to as described above. After washing, the 
microparticles were resuspended in ddH
2
O and placed on a glass slide with a 
coverslip and cross-sectional Z-stacked images were taken on a Nikon A-1 
spectral confocal laser scanning microscope (CLSM) with NIS Elements viewing 
and analysis software. 
To evaluate the particulate release fraction, OVA-AF647-loaded 
microparticles were resuspended in PBST and sent to release at 37 °C. At 
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predetermined time points, a sample of the suspension was removed and 
washed with ddH
2
O before similarly imaging as above via CLSM. Images were 
compared against Alhydrogel that had similarly been loaded with OVA-AF647 
and washed of unbound antigen. 
3.4  Results and Discussion 
3.4.1  Microparticle Fabrication and Physical/Thermal Characterization 
 
The formulation parameters of the ASE PLGA microparticles were selected 
to produce spherical, porous microparticles within the desired size range  
(10 – 60 µm) that demonstrated self-healing when incubated in solution above 
T
g
. After sieving and freeze-drying, approximately 70% of the formulation mass 
had been recovered. The microparticles were well formed and highly porous as 
observed via SEM (Fig 3-2A). While other formulations were attempted, they 
either did not result in well-formed and porous microparticles, or 
demonstrated inferior OVA loading. Of particular note, when the PLGA 
concentration was reduced to 250 mg/mL, a significant portion of the 
microparticles were malformed, and appeared to have collapsed, likely due to 
an inability to withstand the osmotic force created by the double emulsion 
(Supp. Fig 3-1). The hydrated microparticles had a volume-weighted mean 
diameter of 35.0 µm, with 80% of particles falling between 21.6 and 55.7 µm 
(Supp. Fig 3-2). This size is larger than the limit up to which professional 
phagocyte cells can internalize a particle (28). Thus, in vivo, any encapsulated 
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antigen will likely be hidden from the immune system until it is released from 
the microparticles. 
One advantage of the ASE loading strategy is it allows formulation 
optimization to largely take place in the absence of protein. This reduces the 
amount of potentially expensive protein wasted during pilot studies to create 
microparticles. Thus, while 70% of the microparticles fell within the desired 
range, the excluded microparticles did not contain protein at this stage, further 
reducing waste and costs. 
After incubation in the loading gamut, which included two days at 42 °C, 
self-healing of the surface pores was apparent (Fig 3-2B). This healing and 
rearrangement of the surface pores serves to trap some of the antigen-
Alhydrogel complex inside the polymer, slowing release by closing the diffusion 
path out of the microparticles (19,21). While the microparticles are still porous, 
suggesting self-healing was not absolute, they appear mostly smooth with 
smaller pores. Previous research into self-healing suggested both that larger 
pores may not be capable of fully healing within a reasonable time-frame 
(24,25), and that the presence of Alhydrogel may partially hinder the self-
healing process (19). Surface tension, which drives self-healing, falls during 
incubation above T
g
, further slowing healing (25). This suggests that pores that 
do not heal early in the incubation may not be able to fully heal, regardless of 
incubation time or temperature, within reason. Additional loading gamuts were 
tested, including removing microparticles after two days at room temperature, 
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two days at 37 °C, or up to four days at 42 °C (Supp. Fig 3-3). Microparticles 
incubated at room temperature showed no change in surface morphology and 
remained buoyant – suggesting incomplete water-uptake. Microparticles 
incubated at 37 °C showed limited self-healing. This is consistent with previous 
work suggesting healing does not occur below T
g
, and is slow in the few degrees 
above it (24). Microparticles incubated at 42 °C for four days had pronounced 
and significant healing, but like those incubated for two days at  
42 °C, were also not fully healed. Four days at 42 °C was deemed too long and 
too damaging to be useful, so was not explored further. While complete self-
healing was not observed with this formulation, it may be possible to promote 
it with the addition of hydrophobic plasticizers to the polymer phase to further 
drop T
g
, as has been previously described (19). 
The 2nd heating curve of mDSC thermographs indicated a T
g
 for the neat, 
lyophilized microparticles of 46.5 °C. This high T
g
 is ideal, as it suggests the 
microparticles are likely to be shelf-stable – not requiring refrigeration so long 
as care is taken to keep out moisture. Since the microparticles do not contain 
protein, it is reasonable to conclude that a healthcare provider could store them 
in such a manner. After hydration and loading, however, the T
g
 had fallen to 
32.6 °C (Table 3-1). This is consistent with plasticization of the polymer by 
water, dropping the T
g
 (29), and further supports the aforementioned healing 
behavior. This T
g
 is also below physiologic temperature, so while the dry 
microparticles are shelf-stable, once resuspended they will degrade/release 
antigen (14). 
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3.4.2  Active Self-Encapsulation of Vaccine Antigens 
 
To optimize loading conditions, OVA was used as a model antigen. Various 
antigen concentrations and sample volumes were added to a set mass of 
microparticles (20 mg) to maximize w/w loading % and encapsulation efficiency 
(Table 3-2). When the volume was maintained at 1000 µL and concentration was 
lowered, loading decreased significantly with concentration. But when 
concentration was maintained at 1000 µg/mL, the effect of decreasing volume 
on loading was much less pronounced. However, there was a significant effect 
on EE%. The two most optimal combinations were both at a concentration of 
1000 µg/mL, and volumes of either 500 µL (which produced the best loading, 
1.6% w/w) or 300 µL (which produced the best EE%, 90.7%). Thus, while one of 
the advantages of ASE is less wasted antigen, these studies suggest it is best to 
work with lower volumes than lower concentrations, but that there is versatility 
to change parameters depending on the importance of EE% or loading, which 
may change based on the antigen/disease of interest. It is believed that the 
increase in loading observed between 1000 µL and 500 µL (1 mg/mL each) is 
due to a change from a 2.0 mL microcentrifuge tube to a 0.6 mL option. This 
produced better mixing, and also limited the air-water interface. Microparticles 
at this interface may not load or heal properly, as has been previously observed 
(26). For future studies, the parameters producing the highest loading were 
selected (500 µL, 1000 µg/mL). 
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To test the effects of the loading gamut, microparticles were incubated at 
various temperatures ramps (Fig 3-3). All microparticles incubated at 42 °C with 
at least one prior day at lower temperatures had statistically significant loading 
of ~1.6% w/w regardless of additional time at 42 °C. Microparticles incubated 
only at 42 °C had slightly attenuated loading. Allowing the microparticles to 
incubate at lower temperatures allows time for the antigen to diffuse into the 
pores and bind Alhydrogel before the healing process begins. Microparticles 
incubated up to 37 °C had only slightly reduced loading, but also showed 
attenuated self-healing. Microparticles incubated only up to room temperature 
demonstrated significantly lower loading and showed no signs of self-healing. 
For future studies, microparticles were loaded using a temperature ramp of two 
days at 4 °C, one day at room temperature, and two days at 42 °C. Again, this 
demonstrates the versatility of the ASE approach. While higher temperatures 
are optimal, it is still possible to load the microparticles at lower temperatures 
if working with thermolabile antigens, or if heating instrumentation is not 
available. Furthermore, the ease with which it can be performed could allow it 
to be carried out directly at the point of care with minimal scientific 
supervision.  
To visualize the distribution of antigen encapsulated in PLGA 
microparticles after ASE, microparticles were loaded with an Ovalbumin-
AlexaFluor 488 conjugate (OVA-AF488). Cross-sectional images were taken to 
develop a Z-stacked image. Fig 3-4 shows a cross section image with orthogonal 
images alongside. This image confirms that the antigen is reasonably well 
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distributed throughout the microparticles. The smaller microparticles appear 
most homogeneous, suggesting uniform antigen distribution. The larger 
microparticles fluoresce most brightly towards their surface. This could be due 
to: A) inability of the antigen to diffuse deeply into the larger microparticle 
core, B) non-uniform distribution of Alhydrogel within the microparticles, or  
C) attenuation of laser strength and/or fluorophore emission through the 
thickest part of a dense opaque polymer material (30).  
Multiple antigens were evaluated for their ability and capacity to load into 
the same microparticle formulation. Table 3-3 shows the loading capacity of 
OVA, rHBsAg, rPA, and F1-V into the microparticles, as well as their adsorption 
capacity to Alhydrogel. Also included was Tetanus Toxoid (TT), which was not 
evaluated here, but was previously shown to successfully load into ASE 
microparticles using a similar formulation (19). All antigens tested could be 
successfully loaded into the microparticles. The rPA and F1-V, however, were 
not thermostable, and required the addition of 20% w/w trehalose to the 
loading solution in order to stabilize the antigen during the loading gamut 
(Supp. Fig 3-4), as has been previously reported (31). While the addition of this 
excipient stabilized the antigen, it also interferes with loading. When 20% 
trehalose was added to OVA controls, loading was reduced by 45% (data not 
shown). 
This data perhaps best demonstrates the vast potential of the ASE 
technique. Shown here are multiple antigens loading into the same 
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microparticle formulation. A different batch of microparticles need not be 
created for each antigen, as would be required of traditional encapsulation 
techniques. Instead, a bulk supply of unloaded microparticles was fabricated. 
These microparticles can be easily stored, and then aliquots of microparticles 
can be taken for loading as needed with whatever antigen is required without 
the need for specialized instrumentation or training. Because Alhydrogel, which 
is already included in many different vaccines, is used as the trapping agent, 
any antigen that can bind to Alhydrogel could be loaded into these 
microparticles. This offers great cost, time, and space saving opportunities, and 
could allow microparticle-based vaccines to reach a wider population than was 
previously practical. 
3.4.3  Antigen Release from PLGA Microparticles 
 
In vitro release of a model antigen, OVA, was observed to occur in two 
phases. Over the first 50 days, there is a controlled release of soluble OVA as 
detected in the release media via SEC (Fig 3-5). This includes roughly 50% of 
total encapsulated antigen released during the first day, an additional 20% over 
the first week, and approximately 5% released slowly over the following month 
or so. The general kinetics of this release matches closely with that of the 
freeze-dried inner-water phase (Alhydrogel + trehalose) and fresh/unprocessed 
Alhydrogel, except for a modest decrease in initial burst. This suggests that the 
fabrication process has likely not altered the native function of Alhydrogel. 
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The second phase of release is that of the Alhydrogel-antigen complex. In 
addition to electrostatic interactions, Alhydrogel is known to undergo ligand 
exchange with many phosphorylated antigens, including those tested here  
(32-36). The fraction of antigen that is ligand bound is generally not recoverable 
in the soluble form (32,37-39). Thus, this protein fraction releases from the 
microparticles as a particulate complex. The complex is difficult to accurately 
quantify and separate from the polymer, and additional research will be needed 
to confirm that this antigen is still antigenically active. However, to visualize 
the behavior of this complex, microparticles were again loaded with OVA-
AF647. Fig 3-6A shows the small complexes created by co-incubation of 
Alhydrogel with OVA-AF647. Figures 6B-F show microparticles loaded with 
OVA-AF647 at various stages of release. Up through day 14, fluorescence is 
localized within the microparticles, which appear spherical and without obvious 
signs of physical degradation. At day 21, the microparticles begin to show signs 
of physical degradation, and what appears to be the Alhydrogel-OVA-AF647 
complex begins to appear outside the microparticles. The degradation of the 
microparticles and subsequent release of the complex is even more pronounced 
at day 28. By day 42, intact microparticles are no longer visible, and the entire 
signal comes from these particulate complexes. This suggests that the complex 
is not able to escape the intact microparticles due to its particulate nature and 
large particle size (40). However, as the microparticles physically degrade, the 
complex is able to escape for presentation to the immune system. These results 
are further corroborated by SEM images of the microparticles taken at 
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equivalent timepoints (Fig 3-7). These images confirm that the microparticles 
maintain their spherical, intact shape through 14 days. At day 21, there are 
obvious signs of physical bulk degradation, and the surface morphology 
appears more smooth. Again, at day 28 the microparticles have lost most of 
their shape, while at day 42 microparticles no longer identifiable. 
To verify that the mass of antigen released as a complex accounts for the 
remaining ~25% of antigen that does not release during the soluble phase, the 
microparticles were subjected to nitrogen analysis (Table 3-4). After 35 days of 
release, the microparticles (and any released complex) were spun down, washed 
with ddH
2
O, and then lyophilized. The powder was mixed to ensure uniform 
distribution, and a sample was analyzed for nitrogen content against EDTA 
(standards), OVA (positive control), and unloaded microparticles also sent 
through 35 days of in vitro release testing (negative control). The PLGA and 
microparticle excipients do not contain nitrogen. Thus, any nitrogen signal 
(after subtracting negative controls) was assumed to be due to remaining 
protein either in the microparticles and/or released as a complex with 
Alhydrogel. While approximately 70% of OVA had released in the soluble form 
by day 35, nitrogen analysis determined the remaining microparticles contained 
27% of the total encapsulated protein, thus accounting for 97% of total 
encapsulated protein. While this technique does not provide information about 
protein structure, it does support the conclusion that the antigen not released 
in the soluble phase is still inside the microparticles, and may be released as a 
complex with Alhydrogel.  
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Taken together, the soluble and particulate release data paints the full 
picture of how release occurs from these microparticles (Supp. Fig 3-5). First, 
there is a quick wave of soluble antigen released, which tapers off by the end of 
the first week or so. This release is caused by counter ions from the release 
media (in this case phosphate) outcompeting the antigen for binding sites on 
Alhydrogel. The soluble antigen then diffuses out of the polymer through the 
existing pore network, slowed somewhat by the partial healing of surface pores. 
The fraction of antigen that is ligand-bound to Alhydrogel remains inside the 
microparticles. Then, starting around the third week, the microparticles begin 
to physically degrade and fall apart, opening up larger pores through which the 
Alhydrogel-antigen complex can escape. The process concludes around week 6 
when the microparticle is fully degraded.  
It is important to note, however, that different antigens may have different 
ratios of electrostatic and ligand-exchange interactions with Alhydrogel. While 
75% of OVA releases in the soluble phase, for the highly ligand-exchanging 
antigen rHBsAg (33) only 25% of encapsulated antigen was released in the 
soluble phase (Fig 3-8). There, the release curve of soluble antigen from 
Alhydrogel, freeze-dried inner-water phase, and the microparticles, is shifted 
down approximately 50%, respectively. The same general release kinetics apply 
as the microparticles behave the same regardless of the antigen.  
It is known that the kinetics of antigen presentation to the immune system 
greatly influence the resulting immune response (12). It is in this way that that 
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the system presented here would be expected to outcompete soluble antigen or 
Alhydrogel-complexed antigen alone. The soluble antigen released may begin to 
prime the immune system, while the microparticles hide the remaining antigen 
from the immune system until they degrade and release the remaining 
complex. This should generate a stronger immune response than presenting all 
the antigen at once, as is done with conventional vaccination. 
3.5  Conclusions 
 
The microparticle system explored here is a useful alternative to 
conventional approaches for loading vaccine antigens inside PLGA 
microparticles for controlled release. Using the Active Self-Encapsulation 
method, high loading of both model and clinical antigens was achieved (up to 
2.3% w/w), along with encapsulation efficiencies of up to 90%. This work is 
distinct from previous results (19) in that it more fully evaluated the ability of 
the system to work with multiple antigens, and better characterized release 
through both the soluble and particulate/complexed phase. Using this system, 
researchers can create and optimize microparticles without needing to include 
potentially expensive antigens, and then test the design first using inexpensive 
model antigens before using clinical options. This could also allow a healthcare 
provider to store bulk quantities of a single microparticle supply, and then load 
with different antigens on a case-by-case basis without requiring special 
equipment. Similarly, by using the common vaccine adjuvant Alhydrogel as a 
trapping agent, any antigen that will bind to Alhydrogel can be loaded into the 
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same microparticles, as shown here with OVA, rHBsAg, rPA, F1-V, and 
previously TT. After incubation, the antigen-Alhydrogel complexes are well 
distributed throughout the microparticles. In vitro testing revealed a biphasic 
release mechanism. First, there is a quick release of soluble antigen that occurs 
mostly over one week, but may extend out longer. Later, the remaining ligand-
bound fraction of antigen releases as a complex only after the microparticles 
have substantially physically degraded (starting at approximately three weeks). 
By slowly exposing the antigen to the immune system, not only may a stronger 
immune response be generated, but it may also decrease reliance on booster 
doses needed to achieve protective immunity. This has the potential to reduce 
vaccination costs and improve vaccine coverage worldwide.  
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Figure 3-1: Schematic of Active Self-Encapsulation loading method. Porous microparticles containing 
trehalose-stabilized Alhydrogel are fabricated and freeze-dried. Microparticles are soaked in an antigen 
solution, antigen enters the pores and adsorbs to Alhydrogel. The solution is then mildly heated, healing 
the pores and entrapping the antigen. Microparticles can then be collected, washed, and utilized. 
 
 
 
 
 
 
 
Figure 3-2: Porous PLGA microparticles self-heal under mild heat. A) Porous microparticles after 
fabrication and lyophilization. B) Partially self-healed microparticles after full loading/healing gamut 
(primarily two days at 42 °C). 
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Table 3-1: Tg of unloaded lyophilized microparticles, and of loaded and hydrated microparticles. The Tg of 
neat microparticles is above typical ambient temperatures, while the hydrated Tg is below physiologic 
temperatures. n = 3 
 
 
 
 
 
 
 
 
 
Table 3-2: Loading % and EE% can be tailored based on loading conditions. Low volumes of higher 
concentrations perform better than high volumes of lower concentrations. (SEM) 
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Figure 3-3: Changes to the loading gamut influence w/w loading. Hotter incubations yield higher loading, 
but additional time has no effect. ** p<.01, **** p<.0001 
 
 
 
 
 
Figure 3-4: Active self-encapsulation results in thorough antigen distribution throughout the 
microparticles. Microparticles were loaded with OVA-AF488. Scale = 100 µm. 
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Table 3-3: Multiple antigens can load into the same microparticle formulation using the ASE technique.  
*
20% trehalose added to the loading solution. 
a
data from Ref (19). (SEM) 
 
 
 
 
 
Figure 3-5: Controlled release of soluble OVA from ASE microparticles mimics the kinetics of antigen 
desorption from Alhydrogel. n = 3, ± SEM. 
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Figure 3-6: Release of Alhydrogel-OVA-AF647 complex from ASE microparticles. 
A) Alhydrogel-OVA-AF647 complex. OVA-AF647-loaded ASE microparticles after, B) 7 d, C) 14 d,  
D) 21 d, E) 28 d, and F) 42 d of in vitro release at 37 °C. Scale = 100 µm. 
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Figure 3-7: ASE microparticles slowly degrade during in vitro release at 37 °C, with significant 
degradation not apparent until 21 days. Electron micrographs of microparticles after A) 7 d, B) 14 d,  
C) 21 d, D) 28 d, and E) 42 d in release. Scale = 50 µm. 
 
 
 
 
 
Table 3-4: The fraction of antigen not released from ASE microparticles during the soluble release phase 
can be accounted for via nitrogen analysis. Approximately 70% of encapsulated OVA was released as 
soluble antigen by day 35. The remaining sample’s mass was found to contain approximately 27% of total 
encapsulated OVA, for 97% total recovery. (SEM) 
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Figure 3-8: Controlled release of soluble rHBsAg from ASE microparticles, freeze-dried inner-water 
phase, and raw Alhydrogel. n = 3, ± SEM. 
 
 
 
Supplementary Figure 3-1: Osmotically collapsed microparticles formed using a 250 mg/mL polymer 
concentration. 
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Supplementary Figure 3-2: Microparticle size distribution. Hydrated microparticles had a volume 
weighted mean diameter of 34.95 µm, with 80% of particles falling between 21.58 and 55.67 µm.  
Specific surface area = 0.184 m
2
/g. Surface weighted mean = 32.57 µm. 
 
 
 
 
 
 
 
Supplementary Figure 3-3: Microparticles do not heal when incubated at room temperature for 2 d (A), 
show minimal healing after 2 d at 37 °C (B), and are not considerably more healed after 4 d at 42 °C  (C) 
than after 2 d at 42 °C (Figure 3-2B).   
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Supplementary Figure 3-4: Stabilization of rPA at 42 °C by the addition of 20% w/v trehalose. 
 
 
 
 
 
 
Supplementary Figure 3-5: Schematic of biphasic release from ASE microparticles. There is an initial 
burst (prime) of soluble antigen released as electrostatically adsorbed antigen desorbs and diffuses out of 
the microparticles. This is followed later (boost) by release of ligand-bound antigen-Alhydrogel complex 
that releases only once physical bulk degradation of the microparticles begins. The ratio of soluble to 
complex release will vary between antigens, depending on their binding mechanisms to Alhydrogel. 
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Chapter 4: Microparticle-based Microneedle Patches for Intradermal 
Vaccination 
4.1  Abstract 
 
Intradermal delivery is an attractive route for vaccine administration due 
to the skin’s potent immune system. However, it is seldom used due to 
difficulties with precise intradermal administration.. Microneedles are a 
promising alternative to conventional hypodermic needles, and are specifically 
designed to deliver therapies into the skin. They cause little pain, can be self-
administered, and are easy to store/dispose. Presented here are proof-of-
concept studies utilizing microneedles to intraderamally deliver controlled 
release polymer microparticles loaded with vaccine antigens. By adding 
controlled release, it is possible to improve the immune response and reduce 
reliance on booster doses. These microparticles can load a variety of antigens, 
and demonstrate in vitro controlled release over greater than one month. Using 
a casting system, antigen-loaded microparticles were loaded into soluble 
microneedle patches, with the microneedles resting on pedestals to improve 
delivery. Each patch contained 204 µg of microparticles, which for the model 
antigen Ovalbumin corresponds to 3.4 µg of antigen. These microneedles 
readily penetrated excised porcine skin, and delivered >50% of their payload 
during a 20 minute application. Histologic cross-sections confirmed localization 
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of microparticles in the dermis after application, and retention at the site of 
application for over one week. The resulting wounds resealed over 2-4 days.  
When used to vaccinate mice, the patches and injected microparticles generated 
a robust antibody response that was as good as or better than conventional 
administration techniques, but without the need for a hypodermic injection. 
These studies show that microparticle-based microneedles have potential as a 
future self-applied, single-dose vaccine delivery system. 
4.2 Introduction 
 
Vaccines are generally considered to be the greatest medical advancement 
in human history. And while they have improved worldwide public health 
immensely, many hurdles remain. For example, in 2014 an estimated 18.7 
million infants did not receive basic vaccines (1). Even in the United States, 
annual influenza coverage struggles to reach 50% (2), with other readily-
available vaccines fairing much worse. Increasing vaccine coverage is likely to 
be one of the most effective means available for preventing a massive public 
health emergency such as the 1918 influenza outbreak that killed nearly 5% of 
the world’s population (3). 
There are many factors that might lead an individual to not receive their 
shots. Additionally, there is much that could be done by scientists to improve 
the efficacy of current vaccines. In the research presented here, a new vaccine 
delivery system is developed that attempts to overcome many of these 
limitations, which is outlined below. 
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A critical and often overlooked limitation of modern vaccines is their 
reliance on hypodermic needles. Vaccines are complex biomacromolecules that 
need to be presented to the immune system, and as such they generally cannot 
be dosed orally. As a result they are often loaded into hypodermic needles for 
intramuscular (i.m.) injection. Logistically, hypodermic needles present several 
issues. They are large, sharp, and sterile, and so require considerable space and 
are difficult to store. Pre-filled syringes must often be kept refrigerated, further 
limiting storage abilities. Otherwise, a healthcare provider must manually fill a 
syringe, which is time consuming and presents the possibility of error. 
Furthermore, after administration used needles are a serious health risk and 
must be disposed of as costly biohazardous waste. Lastly, administration of 
most shots must be done by a healthcare provider. The inability to self-
administer presents numerous shortcomings, both to busy individuals whom 
might not take the time to get their shots, as well as to developing nations 
where the nearest healthcare provider may be very far from the home. Taken 
together, these logistical components of storage, transport, disposal, and staff 
time for administration represent 80% of the cost of vaccination campaigns (4). 
Moreover, there are many aspects that make hypodermic needles disliked by 
patients. The pain, possibility of blood, and needle-phobia are real 
considerations that prevent some patients from finishing vaccine schedules  
(5-7). Finally, from an immunology point-of-view, the intramuscular 
administration route is less than ideal. Muscle has a low resident population of 
professional phagocytes and antigen presenting cells, which are needed to 
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induce immunological memory (4). A more attractive route for immunization is 
by intradermal (i.d.) injection (4). The skin has very high concentrations of 
Langerhans and Dendritic cells, which are potent immunological players (8,9). It 
is frequently observed that when vaccines are administered to the skin, more 
powerful responses are generated, or lower doses produce equivalent 
responses when compared to i.m. injections (4,10,11). The caveat to i.d. 
vaccination has historically been a difficulty precisely accessing the intradermal 
space, or delivering accurate doses (12).   
Microneedles (MNs) are an attractive delivery device for vaccines, as they 
overcome many of the obstacles mentioned above. In brief, they are typically 
patches containing an array of small projections (<1500 µm) that penetrate 
into, but not through, the skin and deliver a therapeutic payload. They are 
specifically designed for intradermal delivery, and come in many varieties  
(12-14). MNs are small and self-contained, so can easily be stored and prepared. 
They generally do not cause bleeding and/or may dissolve entirely, creating 
little or no biohazardous waste. They can be self-applied, cause less pain, and 
are widely preferred by patients over hypodermic needles (15-17). When used to 
deliver vaccines, MNs generally show a significant advantage over i.m. 
injections, typically on par with or superseding i.d. injections (11,18,19). MNs 
have real potential to replace hypodermic needles in many usages, and improve 
worldwide vaccine coverage.  
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One area of research that has been lacking in the microneedle field is that 
of long-acting controlled release. As previously mentioned, most vaccines 
require booster doses. This is generally because modern vaccines induce a weak 
immune response, and the antigen must be re-introduced to bolster the 
response and/or maintain protective levels of immunity (20). Each booster dose 
requires a separate shot and thus a separate trip to a healthcare provider. 
However, it may be possible to develop a single formulation that acts both as 
the priming dose and subsequent booster doses, and can be administered as a 
single, one-time injection. Much work has been done in the field of single-
administration vaccines (21,22). Furthermore, it has been shown that the 
kinetics of antigen presentation significantly affect the immune response, and 
that continuous antigen presentation may be more advantageous than the 
pulsatile method used with booster injections (23).  
A common approach to controlled release is to encapsulate an antigen in 
microspheres of a controlled release polymer such as a poly(lactic-co-glycolic 
acid) (PLGA). These polymers are already used in several FDA-approved 
controlled release medicines. They are biodegradable, biocompatible, and easily 
tailored to work within a desired controlled release time-frame (24,25). They 
slowly degrade in vivo and as they do more antigen is released. While PLGAs are 
currently being investigated as delivery systems for single-administration 
vaccines (25,26), these systems often fall victim to poor antigen stability, as the 
process used to fabricate PLGA microparticles is known to damage sensitive 
antigens (27,28). However, a new system called Active Self-Encapsulation (ASE) 
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largely circumvents this issue by encapsulating antigen after microparticle 
fabrication (29-31).  
Presented here is the combination of controlled antigen release from PLGA 
microparticles with intradermal delivery via microneedles. By using the ASE 
loading paradigm, a variety of antigens can be stability loaded into PLGA 
microparticles for long-acting controlled release. These microparticles are used 
to build a microneedle patch that serves as the delivery device for intradermal 
presentation to the immune system. The bulk of the patch is made of a water-
soluble material that dissolves when applied to the body, thus eliminating 
biohazardous waste while still providing the mechanical strength needed for 
insertion. This material also stabilizes the antigen/microparticles during a 
freeze-drying step that creates a solid-state vaccine, and may lessen the need 
for refrigeration during transit. In whole, this proof-of-concept work shows that 
a microneedle patch based on Active Self-Encapsulating PLGA microparticles is 
a viable system of presenting vaccine antigens to the intradermal immune 
system without the use of hypodermic needles. 
4.3  Materials and Methods 
4.3.1  Materials 
 
PLGA 50:50 (i.v. = 0.60 dL/g, Mw ≈ 55.4 kDa, ester terminated) was 
purchased from Lactel. PLA resin was from Nature Works LLC (Ingeo 
biopolymer 3251D). PDMS was made from Sylgard 184 silicone elastomer from 
Electron Microscopy Services. Poly(vinyl alcohol) (PVA) (80% hydrolyzed,  
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Mw = 9-10 kDa) and Ovalbumin (OVA) was purchased from Sigma Aldrich. 
Recombinant Hepatitis B surface antigen (rHBsAg) was from Arista Biologics. 
Alhydrogel 2% was from Invivogen. OVA-AlexaFluor 488 and  
OVA-AlexaFluor 647 were from Life Technologies. Porcine ear tissue was 
obtained from the Univeristy of Michigan Animal Surgery Operating Rooms 
(ASOR) Laboratories, and was stored at -20 °C until use. All chemical were 
analytical grade or better. The housing and handling of all experimental 
animals was in accordance with the terms of the University Committee on Use 
and Care of Animals (University of Michigan UCUCA) and all NIH guidelines for 
the care and use of laboratory animals. 
4.3.2  Preparation of Active Self-Encapsulating PLGA Microparticles 
 
w/o/w double-emulsion porous PLGA microparticles were prepared via 
solvent evaporation adapting on methods previously reported (29). 350 mg 
PLGA was dissolved in 1 mL dichloromethane. The inner-water phase was 
prepared by concentrating Alhydrogel to 6.35% via centrifugation and removal 
of excess solution, then 8% (w/v) trehalose was added and the slurry was mixed. 
0.2 mL of the inner-water phase was added to 1 mL of the dissolved polymer 
phase, then homogenized for 1 minute at 17k rpm on a Tempest I.Q.2 Sentry 
Microprocessor. 2 mL of a 5% (w/v) PVA solution was then dumped into the 
PLGA and vortexed for 50 s. Lastly, the w/o/w emulsion was poured into  
100 mL of a 0.5% (w/v) PVA solution and hardened under rapid stirring for  
3 hours. The resulting microparticles were passed through a 60 µm and 10 µm 
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sieve in series and washed with ddH
2
O to remove excess PVA. The 
microparticles were then centrifuged (200 g, 5 min) to remove excess liquid, 
frozen by submersion in LN
2
, and lyophilized for 48 h. 
4.3.3  Loading of Vaccine Antigens in ASE Microparticles 
 
Active self-encapsulation of model and clinical vaccine antigens was 
modified from previously reported methods (29). Flocculated OVA was 
resuspended at a stock concentration of 1 mg/mL in 10 mM MOPS buffer,  
pH 7.4. rHBsAg was first buffer exchanged from PBS to MOPS using Microcon 
centrifugal filter devices with a 10K MWCO and following the provided 
guidelines, then brought to a 1 mg/mL stock in MOPS. 0.5 mL of 1 mg/mL 
antigen solution was added to 20 mg microparticles in a low protein-binding 
0.5 mL microcentrifuge tube. The tube was protected from light and rotated for 
2 d at 4 °C, 1 d at room temperature, and 2 d at 42 °C. After incubation the 
suspension was centrifuged for 5 min at 6010 rcf and the supernatant was 
removed and saved for analysis. The microparticle pellet was transferred to a  
2 mL low protein-binding microcentrifuge tube and washed 3X with MOPS. 
Loading and encapsulation efficiencies (EE%) were determined using the 
following formulas using the lost mass of antigen from the loading solution 
compared against positive controls. 
% w/w loading: 
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑏𝑦 𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
 × 100  
EE%: 
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑏𝑦 𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑖𝑛 𝑡ℎ𝑒 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
 × 100 
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4.3.4  Preparation of Microneedle Patches, Including Masters, Molds, and 
Pedestals 
 
PLA MN masters were a generous gift from the lab of Dr. Mark Prausnitz at 
the Georgia Institute of Technology. The fabrication of these masters has been 
described elsewhere (32). Briefly, the patches consisted of a 10 X 10 array of 
pyramidal MNs (300 µm X 300 µm X 600 µm) with tip-to-tip spacing at 640 µm. 
From these masters, PDMS molds were cast and used to make subsequent MN 
patches of equivalent geometry. 
To make standard MN patches (lacking a pedestal), antigen-loaded 
microparticles were first washed 3X with MOPS, then resuspended in cold 
ddH
2
O at an approximate concentration of 40 mg/mL and kept on ice. 25 µL of 
the microparticle suspension was pipetted onto the surface of the PDMS mold, 
and the mold was pulled under vacuum for 10 mins at approximately 25 in.Hg. 
Excess suspension was then removed and returned to the stock for reuse. The 
mold was then centrifuged for 10 mins at 3220 rcf at 4 °C. Excess 
microparticles were removed from the surface of the mold via gentle tape-
stripping. Approximately 90 µL of a 40% PVA + 30% sucrose (w/v) solution was 
then applied over the molds, and pulled under vacuum for 30 mins. The 
patches were then allowed to dry in a fume hood overnight before being 
demolded and trimmed of excess material around the edges to form a ~1 cm2 
square patch. The patches were then submerged in LN
2
 and lyophilized for  
>48 h. Patches were stored under desiccation at 4 °C until use. 
103 
 
The pedestal masters were 3D printed with assistance from the University 
of Michigan 3D lab using a ProJet 3500 HD Max printer. The pedestal was 
modified from lithography methods previously described (33). It consisted of a 
10 X 10 array that could be overlaid onto the MN mold (center-to-center spacing 
of 640 µm), made of pyramidal trapezoids with a 300 µm wide square base,  
800 µm tall, and a 130 µm wide square top. After fabrication the mold was 
cleaned of printing oil, then a PDMS mold was cast from the structure. From 
this mold the part was recast using the same PVA/sucrose mixture used to 
make the microneedles, dried, trimmed, and demolded. 
To create pedestal patches, the aforementioned patch process was carried 
out identically through the first centrifugation step. After tape-stripping away 
excess surface microparticles, 25 µL of the PVA/sucrose mixture was vacuumed 
onto the mold for 10 minutes while the mold was covered to prevent 
evaporation and premature hardening of the patch. Surface PVA/sucrose was 
then removed using a razor under a stereomicroscope (Nikon Olympus). A 
pedestal part was then aligned with the MN cavities and gently pressed in place. 
The patches were then allowed to dry in a fume hood overnight, demolded, and 
freeze-dried. Each patch used in this study was visualized on a 
stereomicroscope to ensure microneedle quality. Malformed patches were 
occasional, but discarded. 
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4.3.5  In vitro Release and Stability of Antigens from Microparticles and 
Microneedles 
 
For microparticles, in vitro release was done by resuspending 
microparticles (20 mg, unless otherwise noted) in 1 mL PBST (PBS + 0.02% 
Tween 80), pH 7.4. For MN patches, four patches were placed in a 2.0 mL 
microcentrifuge tube and dissolved in ddH
2
O over one hour and washed 3X. 
The resulting microparticle pellet was then resuspended in 0.25 mL PBST. 
Samples were shaken (240 rpm) at 37 °C and at each timepoint (1, 3, 7 days and 
weekly thereafter), the microparticles were centrifuged 5 mins at 6010 rcf and 
the full release media was removed for antigen analysis via size-exclusion 
chromatography (SEC) and replaced with fresh PBST. 
To assess the stability/immunoreactivity of OVA released from MNs, the 
previously mentioned release media was further quantified using a commercial 
OVA-specific enzyme-linked immunosorbent assay (ELISA) kit (Alpha 
Diagnostics). The kit was used in accordance with the manufacturer’s 
instructions. Samples were diluted with the provided sample diluent based on 
SEC data to fall within the range of standards. The plate was read at 405 nm 
using a Synergy Neo plate with Gen5 software, and analyzed in GraphPad Prism 
software using a 4-parameter logistic curve.  
4.3.6  Size Exclusion Chromatography of Antigens 
 
Unless otherwise stated, antigen concentration was determined by SEC 
using either high or ultra performance liquid chromatography (HPLC/UPLC). In 
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either case, the mobile phase consisted of PBS, pH 7.4 flowed at 1 mL/min 
(HPLC) or 0.4 mL/min (UPLC). Injection volumes were 50 or 10 µL for HPLC and 
UPLC, respectively. All samples were filtered through 0.45 µm filters prior to 
injection. A TSKgel G3000SWxl column was used for HPLC and an Acquity BEH 
SEC (4.6 X 150 mm) column was used for UPLC. UV detection was done at  
215 nm. All samples were carried out in triplicate or greater. 
4.3.7  Microneedle Penetration and Microparticle Deposition/Histology 
 
For all studies evaluating mechanical integrity of microneedle patches, 
excised porcine ear tissue was used. The shaved inner skin with cartilage 
attached was separated from the outer skin and subcutaneous fat with a razor, 
and pinned taut on a cutting board. Standard and pedestal patches were gently 
placed tip-down onto the skin, and pressed in firmly with the thumb for 10 s. 
The patch was then removed and Gentian Violet (Ricca Chemical Co.) was 
applied to the application site for one minute before being wiped away with an 
alcohol pad. The application site was then cut away and imaged on a 
stereomicroscope (n=5 for each patch type). 
To evaluate depth of MN penetration/microparticle deposition, 
microparticles loaded with OVA-AF488 were fabricated into MNs and the 
experiment was performed similar to above, except patches were held on the 
tissue for 5 minutes with pressure, then placed in a 37 °C chamber at 98% 
humidity for 15 additional minutes to allow the MNs to dissolve. The backing of 
the patches was gently removed and the application site tissue was cut out and 
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embedded in OCT compound, which was subsequently dipped in isopentane 
chilled by surrounding LN
2
. The samples were then cut into 50 µm sections 
using a Leicia 3050S cryostat onto Superfrost+ microscope slides. Slides were 
thawed and immediately imaged on a fluorescent stereomicroscope.  
4.3.8  Microparticle Mass Balance and Fraction of Dose Delivered 
 
To determine the mass of microparticles in each patch, four patches were 
placed in a microcentrifuge tube and the PVA/sucrose material was dissolved 
with ddH
2
O and washed 3X before drying in a vacuum oven at 40 °C overnight. 
The resulting sample was weighed and the mass divided to determine the mass 
per patch. 
To determine the mass of microparticles delivered upon application of the 
MN patches, a live animal model was necessary.  Using male nude BALB/c mice 
(Charles River), the application site was removed of any light hair using 
depilatory cream (Nair®) one day in advance of patch application. The mice 
were anesthetized via vaporized isoflurane, and placed on a heated pad to 
maintain body temperature. A fold of skin from the dorsal flank was pulled 
from the body and held taut on a cutting board. A microneedle patch was 
gently placed on the skin, and pressed in with the thumb for 5 mins. Pressure 
was then removed and the patch was kept on the skin for an additional  
15 mins. The remaining portion of the patch was then removed and placed in a 
microcentrifuge tube. Again, four patches were used per sample (n=3 samples). 
The patches were then dissolved in ddH
2
O and washed 3X, then dried in a 
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vacuum oven at 40 °C overnight. To account for residual animal tissue that was 
picked up by the patches, the mass of microparticles remaining in the patches 
after application was determined by Gel Permeation Chromatography (GPC). 
The pellet was resuspended in 0.5 mL tetrahydrofuran (THF) and rotated for  
30 mins to dissolve the polymer. The samples were then spun for 5 mins at  
6010 rcf to pellet the tissue and the supernatant was run on a Waters model 
2414 IR detector with a Styragel HR 5E THF column in series with a Styragel HR 
1 THF column both kept at 35 °C. The mobile phase of THF was pumped at  
0.5 mL/min, and the full run time was 20 mins. Samples were run against 
standards made from known masses of microparticles dissolved in THF. 
4.3.9  In vivo Microparticle Tracking 
 
To evaluate the residence time and tissue distribution of microparticles 
and antigen administered via MN patches, microparticles were first loaded with 
OVA-AF647 and incorporated into pedestal MN patches. The patches were then 
applied to male albino C57BL/6J mice (Jackson Laboratories) as described 
above. Two patches were applied per mouse, to the left anterior and right 
posterior dorsal flank. At predetermined time-points, the whole animal was 
anesthetized and imaged using a PerkinElmer IVIS Spectrum imaging system. 
Fluorescence data was processed using a region-of-interest (ROI) analysis with 
background subtraction using Living Image 4.5 software. Other study groups 
included mice given an i.d. injection to the same locations of an equivalent 
delivered dose of OVA-488-loaded microparticles or soluble OVA-AF647. Also 
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included were smaller (mean diameter = 7.1 µm) calcium phosphate-based 
microparticles (supplementary information) and pedestal patches made from 
said microparticles. Mice were kept on an alfalfa-free diet to reduce 
autofluorescence. Depilatory cream was not reapplied during the study, but 
hair was kept trimmed using electric razors (n=4 mice/group, 2 applications 
per mouse). 
4.3.10  Skin Resealing  
 
Evaluation of skin resealing kinetics was determined in tandem with the in 
vivo microparticle tracking study mentioned above. Transepithelial water loss 
(TEWL) was measured using a Delfin Technologies VapoMeter with DelfWin 4 
capture software. Study groups consisted of application of A) ASE 
microparticle-loaded pedestal patches, B) pedestal patches loaded with calcium 
phosphate-based microparticles, C) vehicle-only patches (pedestal MN patches 
made of only PVA/sucrose, no microparticles), and D) PLA master patches (no 
pedestal) that did not dissolve or considerably break when applied to animals. 
Three measurements were taken per application site, per animal, at each 
timepoint, and the TEWL chamber was allowed to re-equilibrate to 
environmental conditions before each measurement. To measure TEWL, the 
VapoMeter was gently pressed against the application site without any manual 
tension applied to the skin. Data is presented as percent increase over an 
application control using ANOVA with Fisher’s LSD. The application control 
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consisted of a flat PVA/sucrose mock patch that did not contain any 
microneedles, but was applied similar to other groups.  
4.3.11  Immunization Study 
 
Male C57Bl/6 (for OVA groups) or BALB/c (for rHBsAg groups) mice,  
5-6 weeks old, 5 mice/group, were purchased from Jackson Laboratories.  
One day prior to priming and booster immunization the application site for MN 
patches or i.d. administered groups was shaved and depilatory cream was 
applied, or just shaved for i.m. administered groups. On day zero mice were 
immunized with either A) two pedestal microneedle patches, or equivalent 
delivered antigen dose from, B) i.d. microparticles, C) i.m. microparticles,  
D) Alhydrogel-adsorbed antigen, or E) soluble antigen. A sham group received 
patches containing microparticles that did not contain antigen. To evaluate the 
controlled release potential of the system, additional groups received a double 
dose on day zero of pedestal MN patches, i.m. microparticles, or Alhydrogel-
adsorbed antigen. These groups did not receive a booster. Booster doses for 
other groups were given 21 days after the priming dose.  
To evaluate antibody titers, blood was drawn on days 20 and 42 via 
submandibular bleed. Serum was separated using Microvette 500 Zgel serum 
collection tubes centrifuged for 5 mins at 10,000 rcf. Serum was stored at  
-80 °C until analysis. Serum samples were analyzed by the University of 
Michigan Cancer Center Immunology Core for IgG, IgG1, IgG2c, and IgA via 
ELISA. Antigen-specific IgG1 isotype was used as a standard for all IgGs to 
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determine relative concentration. Data was compared using one-way ANOVA 
with Tukey’s post-test via GraphPad Prism® software. 
To evaluate the nature of the cytokine response produced after 
restimulation of splenic lymphocytes, all mice were euthanized on day 42 and 
spleens were collected under sterile conditions. Splenocytes were collected by 
grinding each spleen through a 70 µm nylon strainer. Red blood cells were 
lysed with ACK lysing buffer and the cells were washed 3X with sterile PBS 
before being resuspended in RPMI 1640 media supplemented with glutamine, 
10% FBS (10%), 1 U/mL penicillin + 1 µg/mL streptomycin, 55 µM 2-
mercaptoethanol, MEM non-essential amino acids (1%), 1 mM Sodium Pyruvate, 
and 10 mM HEPES. Cells were then plated at 5 x 105 cells/well in a 96-well plate 
and stimulated with media (negative control) or 25 µg/mL whole antigen (OVA 
or rHBsAg). Positive controls were pooled from each spleen within a group and 
stimulated with 2 µL/mL PMA/ionomycin (cell stimulation cocktail). Cells were 
incubated for 96 hours at 37 °C with 5% CO
2
 before collecting the supernatant 
and storing at -80 °C. Concentrations of IL2, IL6, IL10, and TNFα were analyzed 
via ELISA through the University of Michigan Cancer Center Immunology Core. 
Stimulated cell supernatants were compared against negative controls using 
Student’s t-test. 
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4.4  Results and Discussion 
4.4.1  Microparticle Fabrication, Loading, and Release 
 
A detailed evaluation of the microparticles used in these studies is 
provided in Chapter 3 of this dissertation. 
4.4.2  Fabrication and Evaluation of Microneedle Patches Containing 
Microparticles 
The process utilized here proved to be a reliable and consistent method for 
fabricating MN patches containing PLGA microparticles in the microneedles. 
This represents the first known occurrence of PLGA microparticles in this size 
range (10–60 µm) being successfully encapsulated into microneedles, and is the 
first work to utilize PLGA microparticles loaded via the Active Self-
Encapsulation system in this manner. When making standard patches, 
microparticles could be readily observed in the microneedles, with only a 
minute amount of particles in the backing (Fig 4-1 A&B). The process was 
effective at minimizing microparticle waste, as excess microparticles used in 
the first suspension cast could be recovered. Only after centrifugation and tape 
stripping were microparticles lost. In future work, it may be possible to more 
accurately manipulate the molds to minimize loss, such as through direct 
micropipetting into individual microneedle cavities. It is important to minimize 
or prevent microparticles from sitting in the backing, as any fraction of the 
dose localized to that space is unlikely to be delivered upon application. 
Furthermore, this approach was easily adapted to include a pedestal design 
that increased the functional length of the MNs while keeping the 
112 
 
microparticles localized to the microneedle portion (Fig 4-1 C&D). While 
pedestal-style patches are becoming more frequent in microneedle literature as 
their necessity becomes apartment (further described below), previous designs 
utilized either a non-biocompatible support structure (which must be removed 
and may be considered biohazardous waste), or included drug in the pedestal 
portion that was not delivered (32,33,35). Here, however, the full patch is made 
of a dissolvable material, allowing the patch to be applied and left on the skin 
until it fully dissolves. By excluding microparticles from the pedestal, the 
fabrication process became more complex, but reduced antigen waste and may 
improve downstream variability. 
Additionally, utilizing 3D printing proved to be a cost-effective method for 
fabricating the pedestal master. Alternative pedestals from the literature have 
relied on photolithography, which can run 10–100X the cost of 3D printing. 
Since these parts did not require a sharp tip or smooth edges, as they were not 
intended to directly penetrate tissue, the limited resolution of current 3D 
printing was not a factor. Once the part was fabricated, a mold was made and it 
was recast using the dissolving PVA/sucrose mixture used in the microneedles 
(Supp. Fig 4-1). Creating a pedestal MN patch involved additional manual 
manipulation, as excess PVA/sucrose had to be removed with a razor, and the 
pedestal part was manually aligned with the MN cavities and pressed in place. 
While this occasionally resulted in malformed patches, advances in automation 
could greatly improve this process. While the standard microneedles had a 
height of 600 µm, and the pedestal part was 800 µm tall, the final tip-to-base 
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height of the pedestal patches was 1183 ± 6 µm, suggesting roughly 200 µm of 
overlap between the pedestal and the microneedle, which is confirmed by 
confocal imaging (Fig 4-1D). 
To determine the mass of microparticles that could be packed into a patch, 
the patches were dissolved, washed, and massed. The standard patches 
contained 244 µg of microparticles, while the pedestal patches contained  
208 µg (Table 4-1). The difference in mass likely results from the additional 
manipulation required of the pedestal patches; possibly from pulling some 
microparticles out of the mold, or doing a more complete job of removing 
microparticles from the backing. Focusing on a model antigen, OVA, which 
loads into the microparticles at 1.64% (w/w), this corresponded to a final 
antigen dose of 4.0 and 3.4 µg/patch for standard and pedestal patches, 
respectively. Because different antigens load at different levels into the 
microparticles, this dose will mildly increase or decrease with different 
antigens. To adjust dosage, several options present, such as changing the 
number of microneedles in the array, using multiple patches, or diluting the 
microparticles. It does not seem likely that more microparticles in this size 
range could be packed easily into a MN without changing the overall geometry. 
4.4.3  In vitro Release and Stability 
 
In vitro, the MN patches demonstrated controlled release of soluble antigen 
(OVA) over approximately one month (Fig 4-2). To evaluate this, microparticles 
were loaded with antigen, either OVA (Fig 4-2) or rHBsAg (Supp. Fig 4-2) and 
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loaded into microneedle patches. The patches were dissolved in and washed 5X 
with ddH
2
O to remove PVA/sucrose binding material prior to starting the 
release study in PBST. While this was a necessary step to ensure accurate 
analysis, it represents a considerable discrepancy between these in vitro results 
and possible in vivo predictions. In vivo the dissolution of the PVA/sucrose 
binding material is expected to take considerably longer than in vitro, as 
interstitial fluid must be recruited to the application site, dissolve the material, 
and then be cleared to allow complete dissolution and subsequent liberation of 
the microparticles. In addition, since the patch has been lyophilized, the 
microparticles must be hydrated as well in order for release to begin (36). In 
brief, the burst release observed on day one is expected to be delayed in vivo.  
The microparticles and MN patches demonstrate similar release kinetics, 
but with the microneedles’ release curve shifted downward 10-15% in total 
cumulative release. This could be due to a variety of factors including,  
A) unrecorded antigen release while dissolving the PVA/sucrose binding 
material, B) a change in release mechanism or damage to the antigen caused by 
the microneedle fabrication process – likely the application of the PVA/sucrose 
material or the lyophilization process (37), C) difficulties accurately 
determining the amount of antigen in the microneedle patches, or D) an 
increase in binding avidity between the antigen and Alhydrogel adjuvant 
brought on by post-adsorption lyophilization. For example, when OVA-loaded 
microparticles were freeze-dried without cryoprotection and then evaluated for 
in vitro release, similar release kinetics were observed but with a significant 
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downward shift (Supp. Fig 4-3), possibly suggesting that more antigen is now 
ligand-bound to Alhydrogel (38). In any case, the remaining antigen that was 
not released as a soluble fraction was likely released as a particulate complex 
ligand-bound to Alhydrogel. A detailed explanation and evidence of this 
process is outlined in Chapter 3 of this dissertation.  
To evaluate the immunoreactivity/stability of antigen after patch 
fabrication and during in vitro release, antigen concentration as determined by 
SEC was compared to that determined via ELISA (Fig 4-3). The measurements 
were found to be in good agreement (generally near 100% immunoreactivity), 
suggesting that the antigen was not damaged during the patch fabrication 
process. There is a modest decrease in immunoreactivity at some later time 
points, possibly due to the increased length of the sampling interval, and/or 
that the soluble antigen may become less stable over time. 
4.4.4  Microneedle Penetration and Microparticle Deposition 
 
To assess the ability of the microneedles to penetrate skin, patches were 
manually applied to excised porcine tissue and the resulting microchannels 
were stained with Gentian Violet. Both standard and pedestal patches were 
evaluated (Fig 4-4A,B), n=5. For standard patches, all five patches tested 
produced 100 clearly identifiable microchannels, suggesting the patches 
possess the mechanical integrity necessary to penetrate skin tissue. Pedestal 
patches produced an average of 98 (±2) microchannels. This is likely due to a 
combination of factors such as: A) poor alignment of the pedestal with the 
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microneedles, B) imperfect microneedle tips due to excess force used during 
patch fabrication, C) decreased structural integrity due to the addition of the 
pedestal, or D) non-uniform pressure during application, which is exacerbated 
by the longer microneedles.   
To verify that after the MNs penetrate the skin they dissolve intradermally 
to deliver microparticles, patches were fabricated with microparticles loaded 
with OVA-AF488. These were applied same as above, but the patch was allowed 
to remain in the tissue for 20 minutes to dissolve. After removing the patch, the 
tissue could be fluorescently imaged to visualize the microparticles (Fig 4-4C). 
The fluorescence is localized to the grid pattern, strongly suggesting that the 
microneedles dissolve intradermally and release the microparticle payload, and 
the microparticles do not spread out either on the surface of the skin or within 
the tissue. 
Afterwards, the tissue was frozen and cryosectioned to visualize cross-
sections of the skin at the application site. Fig 4-4D shows a representative 
cross-section of the tissue, and confirms that microparticles had been 
intradermally deposited via the MN patches. Together, Fig 4-4C and 4-4D 
suggest that microparticles are not left on the surface of the skin where they 
would be inactive, but rather are deposited below the stratum corneum, mostly 
in the dermis.  
After removing the patches in the aforementioned studies, it was apparent 
some microparticles remained on the patch and had not been deposited. To 
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quantify this, a live animal model was necessary to account for the temperature 
and recruitment of interstitial fluid necessary to dissolve the patches. Standard 
and pedestal patches were applied to hairless mice as described above. Images 
of the patches after application are shown in Supp. Fig 4-4. To account for hair 
and tissue that was picked up by the patches, a GPC method was developed to 
determine the ratio of PLGA mass in an applied patch versus a neat patch. As 
shown in Table 4-1, an applied standard patch still contained 75% of the 
original PLGA, while a pedestal patch only contained 45%. The inability of 
microneedle patches to deliver 100% of the dose located in the microneedles is 
well established in the literature (32,39,40). This is typically attributed to the 
elasticity of the skin preventing the entirety of the microneedles from entering 
the dermis for delivery, and is the motivation for pedestal designs as described 
here and elsewhere (32,33,35). While the pedestal improved delivery, and thus 
was used for further animal testing, delivery was still not complete. This is 
likely due to the tip of the microneedles breaking off or dissolving immediately 
upon penetrating the stratum corneum and preventing the microneedle from 
inserting as deeply as would otherwise be possible. Cross-sectional images of 
microparticles imbedded by standard or pedestal patches also showed that the 
pedestal patches only had a modest improvement in maximum microparticle 
deposition depth (data not shown). Thus, future work could investigate using 
either a stronger and/or slower-dissolving material in place of the PVA/sucrose, 
or possibly coating the tip of the microneedles with a material to enhance their 
strength. 
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4.4.5  Skin Resealing via TEWL 
 
A potential concern for advancing MN technologies is the wounds caused 
to the skin by application of the patch. If these wounds do not close quickly the 
potential for infection exists. Several studies have investigated the ability of 
skin to reseal after application of MN patches, including the ability of 
microorganisms to traverse these microchannels (41-44). Those results suggest 
that the microchannels can close rapidly, ranging from under an hour up to two 
days, depending on the style of MN patch and the skin model used. However, at 
least one study suggests that when the resulting microchannels are occluded, 
the resealing time is greatly increased (44). Furthermore, existing literature 
focuses on the use of solid, non-dissolving type patches, which do not deposit 
any material in the wound. Thus, it was necessary to explore the skin resealing 
kinetics after application of the patches used here in order to evaluate if the 
microparticles, or the PVA/sucrose binding material, affected the skin’s ability 
to close the microchannels.  
All patches were applied identically to shaved mice, and TEWL data was 
recorded at predetermined intervals. Immediately after application, TEWL 
values for all test groups rose significantly (Fig 4-5). The PLA master group 
generated a much higher response than the other groups. This could be 
because these patches were made of a stronger, non-dissolving material, that 
did not significantly deform when applied and thus likely generated larger 
wounds through which more moisture could escape (giving higher TEWL 
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readings). However, it is also plausible that because the other patches deposited 
material in the skin, moisture that would have otherwise escaped was instead 
blocked and used for MN dissolution, yielding a TEWL value that was 
irrepresentably low of actual wound size. 
Within six hours of application, wounds from the PLA master patches had 
already resealed. This is consistent with previous literature suggesting wounds 
made from solid non-dissolving MNs reseal quickly (41,42). Wounds from 
vehicle patches and from patches containing smaller microparticles resealed by 
the end of the first day. Wounds from the standard microparticle patches 
resealed between the second and third day. This data may suggest that material 
deposited in the skin by dissolving MNs acts as an occlusion and hinders skin 
resealing. Furthermore, insoluble microparticles that were deposited in the 
skin, and did not dissolve, further hindered the skin-resealing process, with 
larger particles further slowing the process compared to an equivalent volume 
of smaller particles. 
4.4.6  In vivo Tracking of Fluorescently-loaded Microparticles 
 
While penetration and microparticle deposition studies are useful to 
determine how well the microneedle patches deposit their payload when 
applied, it is also important to determine the behavior of the microparticles and 
antigen in the skin over time. While it is generally understood that soluble 
material will be absorbed into the circulation and/or lymphatics, the behavior 
of larger biodegradable depots is less well characterized. To evaluate this, 
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microparticles were again loaded with OVA-AF647 and fabricated into pedestal 
MN patches. Included again were the smaller calcium phosphate-based 
microparticles, treated similarly. All patches were applied to mice and the mice 
were imaged over time to evaluate the strength and localization of the 
fluorescent signal. Values were compared against i.d. injected microparticles 
(both types) and soluble OVA. 
After administration the application site was highly visible through 
fluorescent imaging, with individual MN channels identifiable (Fig 4-6A). Over 
the next 3-10 days, the application site retained its fluorescence for all patches 
and injected microparticles. After only one day, however, the soluble antigen 
signal was heavily attenuated and was lost entirely by day 3. This suggests that 
microparticles deposited by the MNs are not quickly pushed out of the skin 
either by the rapid turnover of the epidermal layer (45), nor by the general 
movement of the animals. While the signal did decrease faster than was 
anticipated, this was true for the i.d. injected microparticles as well  
(Fig 4-6 B&C). This could be due to A) attenuation of the fluorescent signal, 
either by a cleaving off/degradation of the fluorescent tag, or by 
photobleaching, B) more rapid and complete antigen release in vivo, C) the 
animals manually removing some microparticles while licking/cleaning the site, 
or D) a gradual migration of the depot away from the injection site. However, 
additional studies are needed to further probe this phenomenon. 
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4.4.7   Immunizations  
 
To determine if these MN patches or stand-alone microparticles stimulate 
an immune response, mice were dosed with MN patches or microparticles alone 
containing OVA or rHBsAg. 20 days after OVA priming doses, i.m. and i.d. 
microparticles were the only groups to generate significant anti-OVA IgG levels 
compared to sham control groups (Fig 4-7A). This is consistent with the 
hypothesis mentioned in Section 4.4.3 that MN patches would release slower in 
vivo than is predicted by the in vitro release tests, but that this disconnect 
would not correlate as strongly to stand-alone microparticles. 21 days after 
booster doses however, all microparticle/microneedle groups showed high IgG 
levels compared to sham and soluble OVA, and were as good as or better than 
conventional Alhydrogel-adsorbed antigen. Trends were similar for IgG1 (which 
results from a Th2-mediated response (46)), while IgG2c (which results from a 
Th1-mediated response (46)) was very low for all groups, with only the 
microparticle groups producing slightly significant levels by the end of the 
study. rHBsAg-immunized mice showed similar results at the end of the study, 
with MN-dosed mice showing high levels of total IgG and IgG1 compared to 
sham, and at levels that were again as good as or better than Alhydrogel-
adsorbed antigen (Fig 4-7B). At day 20, however, MN-dosed mice showed no 
response, whereas Alhydrogel-adsorbed rHBsAg was already producing high 
levels of both total IgG and IgG1. This is could be due to the same in vivo delay 
explained for OVA, coupled with the fact that rHBsAg was shown to release 
even slower than OVA (Supp. Fig 4-2). In brief summary, these results suggest 
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MNs and microparticles generate a robust Th2-skewed response, which is as 
good as or better than conventional vaccine approaches. 
When a booster dose was omitted, and the full antigen dose was given on 
day zero, mice immunized with microparticles produced an equivalent 
response to those that received the booster (Fig 4-8). Otherwise, following a 
prime-boost approach generally produced stronger responses than prime alone. 
However, this suggests these formulations warrant further evaluations as a 
single-administration vaccine. 
When harvested splenocytes were restimulated with antigen, the only 
cytokine detected in sufficient quantities was IL-10 (Fig 4-9), which is secreted 
by Th2 cells (46). The immune response resulting from a Th2-type pathway is 
typically associated with a more humoral response, and only a weak or 
undetectable cell-mediated response. This is in agreement with the 
aforementioned IgG data, as well as the failure to detect high levels of antigen-
specific CD8+ cells in the blood of immunized mice (Supp. Fig 4-5). 
As a whole, this proof-of-concept immunization study shows that 
hypodermic needle-free vaccination via ASE microparticle-containing 
microneedle patches is a viable option for further exploration, and that the ASE 
microparticles used in the MNs may be a useful method for controlled antigen 
release. The MN patches produced responses that were generally equivalent to 
i.d. injection of the microparticles, but did not rely on a hypodermic needle for 
injection. This seemingly minor detail actually has enormous consequences for 
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improving vaccine coverage for reasons mentioned above, including higher 
patient acceptability, self-application, and easier storage/disposal. It is 
unexpected that i.m. injection of microparticles produced equivalent or even 
stronger responses than i.d./microneedle administration, as this trend is 
typically reversed in the existing literature (11,47).  
The controlled release potential of these polymer-based delivery systems is 
also apparent in the IgG data. For example, rHBsAg was shown to release more 
slowly from the microneedles than OVA (Fig 4-2 and Supp. Fig 4-2). Before the 
boost, it appears that Alhydrogel-adsorbed rHBsAg is producing a more robust 
IgG response, whereas after boost the responses are nearly equivalent. This 
may suggest that the slower release of this antigen delayed the development of 
the immune response. This is also true of the comparison between the 
microneedle patches and i.d. microparticles, as the patches were shown to 
release antigen more slowly than free microparticles (Fig 4-2). Future work 
would benefit from longer-term studies using a more robust skin model  
(e.g., guinea pigs) to evaluate how the response stabilizes 60 or even 90 days 
after priming, and whether or not the responses continue to increase, as may be 
expected based on previous reports (23).  
4.5  Conclusions 
 
The MN patches explored here are shown to be a promising system for 
controlled release of vaccine antigens without reliance on hypodermic needles 
for administration. By basing the platform on Active Self-Encapsulating 
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controlled release PLGA microparticles, it gives the microneedle patches 
versatility to encapsulate not only various antigens, but also different styles of 
microparticles, as was shown here. These patches, with the addition of a 
pedestal, deliver their payload intraderamally with a simple application process 
that could easily be done by a patient or other non-healthcare professional. In 
vitro and in vivo, the patches show evidence of long acting controlled release of 
antigen (>1 mo). Importantly, they generate immune responses that are similar 
to or better than standard injected vaccines, but without the use of a 
hypodermic needle, and with long-acting results. While additional modifications 
to the system could further improve its utility, this work lays a foundation for a 
self-administered single-administration vaccine system that is applicable to a 
variety of vaccines and thus disease states. 
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Figure 4-1: Light micrographs of microparticle-loaded microneedle patches. A) standard patch,  
B) fluorescent micrograph of standard patch loaded with OVA-AF488-loaded microparticles, C) pedestal 
patch with sulforhodamine B added to the first PVA/sucrose cast, and D) confocal image of individual 
pedestal microneedle containing microparticles loaded with OVA-AF647. Scale = 250 µm. 
 
 
 
 
 
Table 4-1: Microparticle and antigen mass contained within a single standard or pedestal microneedle 
patch. % MPs delivered represents the percent of microparticles delivered to the tissue after a 20 minute 
application on live mice. (SEM) 
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Figure 4-2: Microneedle patches demonstrate controlled release of soluble antigen over approximately 
one month, and follow similar kinetics to the microparticles. Microneedles were washed of PVA/sucrose 
binding material prior to release. n=3, ± SEM 
 
 
 
 
 
 
 
 
Figure 4-3: Antigen released from microneedles remains immunoreactive. Immunoreactivity was defined 
as the ratio of concentration as determined by SEC to concentration determined via ELISA. n=3, ± SEM. 
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Figure 4-4: Microneedle patches readily penetrate skin and deposit microparticles intradermally.  
Top) Micrographs of excised porcine skin after application and staining. A) Standard patch, B) Pedestal 
patch. Bottom) Fluorescent micrographs of tissue after application of pedestal patch loaded with  
OVA-AF-488-loaded microparticles. C) Overhead, D) Cross-sectional. Scale = 1 mm. 
 
 
 
Figure 4-5: Skin resealing as measured by TEWL after application of various microneedle patches. 
Unoccluded microchannels made by non-dissolving PLA patches reseal rapidly, while wounds with 
deposited material reseal slower, with larger occlusions taking the longest. 
**** p <.0001, *** p < .001, ** p <.01, * p < .05. n=8, ± SEM. 
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Figure 4-6: OVA-AF647-loaded ASE microparticles remain in the skin for several days following 
intradermal administration from A) microneedles, or B) i.d. injection. C) Normalized radiance quantification 
of OVA-AF647 signal at the application site, n=8, ± SEM. 
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Figure 4-7: ASE microparticles and microneedles generate a robust antibody response. Serum 
IgG levels at day 20 (Left, prime) and day 42 (Right, boost).  
A) OVA-immunized groups, B) rHBsAg-immunized groups. n=5, ± SEM 
Θ
 Concentrations were determined using an IgG1 standard, and may not be absolute for other 
IgG isotypes.  **** p <.0001, *** p < .001, ** p <.01, * p < .05. 
 
A 
B 
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Figure 4-8: Controlled release potential of ASE microparticles and microneedles. An equivalent dose was 
given either split between prime and booster doses, or given all at once during prime (2X). 
n=5, ± SEM,*** p < .001, ** p <.01, * p < .05. 
 
 
Figure 4-9: Splenocytes restimulated with OVA (A) or rHBsAg (B) produce considerable amounts of 
IL-10, indicative of a Th2-type immune response. n=5, ± SEM, ** p <.01, * p < .05. 
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4.7  Supplementary Material 
4.7.1  Preparation and Loading of ASE Calcium Phosphate-based PLGA 
Microparticles 
 
Smaller ASE PLGA microparticles (median diameter = 7.1 µm) that utilized 
calcium phosphate in place of Alhydrogel were also fabricated. A detailed 
overview of these microparticles is available elsewhere (48).  
4.7.2  Determination of Antigen-specific CD8+ Cells in Peripheral Blood 
 
Antigen-specific CD8+ cell populations in peripheral blood were evaluated 
on day 28 (7 days post-boost) via an MHC tetramer assay as previously 
described(34). Briefly, whole blood was collected via submandibular bleed and 
lysed with ACK lysis buffer and washed with PBS + 1% BSA. The Fc receptor was 
blocked with CD16/32 antibody. Cells were then incubated with PE-labeled 
tetramer (SIINFEKL for OVA groups, IPQSLDSWWTSL for rHBsAg groups – the 
rHBsAg tetramer was only available for BALB/c-background mice) (from MBL 
International) for 30 mins on ice, followed by addition of anti-CD8-APC 
conjugate for an additional 20 mins. Cells were washed and then incubated 
with DAPI to discriminate live and dead cells. Samples were stored on ice until 
read on a Beckman Coulter CyAn 5 flow cytometer with data processing in 
FlowJo software. 
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Supplementary Figure 4-1: A) 3D printed pedestal master part. B) Fluorescent micrograph of a pedestal 
patch loaded with OVA-AF488-loaded microparticles. Scale = 500 µm. 
 
 
 
 
 
 
Supplementary Figure 4-2: In vitro release of soluble rHBsAg from microneedle patches and 
microneedles. n=3, ± SEM. 
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Supplementary Figure 4-3: In vitro release of OVA-loaded ASE microparticles after unprotected 
lyophilization.  
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Supplementary Figure 4-4: Stereomicrographs of (Top) standard, and (Bottom) pedestal patches after 
application to mice. Right images emphasize microparticles via fluorescent imaging. 
 
 
Supplementary Figure 4-5: Neither MNs or MPs show a considerable OVA (A), or rHBsAg (B), specific 
CD8
+
 response at d 28. Alhydrogel produced a statistically significant but still very weak response. 
* p < .05, n=5, ± SEM  
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Supplementary Figure 4-6: Serum IgA titers at day 42 after immunization with A) OVA, and B) rHBsAg. 
n=5, ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Chapter 5:  Conclusions, Significance, and Future Work 
The work presented in this thesis is grounded in the understanding, development, 
and utility of the Active Self-Encapsulation (ASE) loading technique. As pharmaceutical 
discovery and development starts to utilize more sensitive biomacromolecules, ASE is 
likely to be more heavily utilized in controlled release systems, and thus a deeper 
understanding and operational framework will be important.  
In Chapter 2, the self-healing of PLGAs is studied directly in a film model. Self-
healing is the phenomenon on which ASE is based, and thus a deep mechanistic 
understanding of it is critical to successful utility. The primary conclusions of the work 
are that self-healing is driven by high surface tension, which causes creep of the 
amorphous polymer when T > T
g
. This is resisted by the polymer’s ability to flow 
(viscosity). The rate of self-healing is thus dependent on the polymer type, the 
environment, residual stress left from fabricating the polymer device, temperature, 
and the geometry of the pores. This is the first time that self-healing has been studied 
directly in PLGAs, and these conclusions have direct influence on the utility and 
limitations to future ASE systems. 
One of the limitations found in Chapters 2 and 3 are long healing times required 
for full pore closure. While Chapter 2 points out ways in which self-healing can be 
accelerated, such as high temperatures or hydrophobic polymer end-groups, such 
alterations are not always feasible. Thus, future work should focus on external 
methods for accelerating self-healing without significantly damaging the polymer or 
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therapeutic. Possible options are weakly penetrating or selective heat sources, surface 
tension-modifying excipients, or creating microparticles with a high number of smaller 
pores. This could reduce the required healing time to a few hours or less and create a 
more viable option for point-of-care compounding. This would also help overcome the 
thermoliability issues seen with some antigens utilized in Chapter 3, and allow a 
greater number of therapeutics to be utilized in ASE systems. 
Chapters 3 and 4 are dedicated to showing the utility of ASE-based microparticles 
both by themselves, and as part of a more complex delivery system involving 
microneedles. Chapter 3 builds on previous work exploring ASE and shows its 
versatility by successfully encapsulating and releasing a variety of vaccine antigens 
from the same batch of microparticles. It also delves deeper into the various stages of 
antigen release. The work suggests initial burst release is caused by soluble antigen 
desorbing from Alhydrogel (trapping agent) and then diffusing out of the 
microparticles. This is followed by a second phase of Alhydrogel-complexed antigen 
releasing after physical degradation of the microparticles.  
While Chapter 3 is successful in showing that ASE works with a variety of 
antigens, it also suggests that the choice of trapping agent may in fact be more critical 
than previously thought. Because of Alhydrogel’s adsorption mechanisms and the 
challenges of completely healing all surface pores, the desorption of antigen from 
Alhydrogel becomes the rate-limiting factor in the early stages of release. Thus, burst 
release will vary greatly and with limited control as different antigens are utilized. 
Instead, it may be desirable if different antigens could have the same or similar release 
profile. Future work could thus focus on selecting a more uniformly applicable 
trapping agent that will adsorb and desorb to different antigens will similar strength 
141 
 
and kinetics. Alternatively, it could be possible to utilize a mix of different 
microparticle formulations each working with different loading and/or release 
mechanisms such that no one formulation is expected to work with all antigens across 
all stages of release, but is such that the mix of formulations produces a consistent 
outcome with different antigens. 
If the aforementioned limitations can be overcome, the resulting drug delivery 
platform would have enormous potential. As previously mentioned, healthcare 
providers the world over could keep stocks of these unloaded microparticle 
formulations, and then load/compound them with various antigens or other 
therapeutics pro re nata on a case-by-case basis to create long-lasting or single-
administration medications. 
Chapter 4 focuses entirely on utilizing ASE microparticles in a novel drug delivery 
system based on microneedles. Microneedle-based systems eliminate reliance on 
hypodermic needles, which are currently a major hurdle to improving worldwide 
public health. While the microneedle field is currently receiving a lot of research, very 
little of it attempts to add long-term controlled release elements, which could lead to 
the development of a self-administered single-administration vaccine. The work done 
in Chapter 4 outlines proof-of-concept development and testing of such a system 
utilizing the ASE microparticles explored in Chapter 3. The platform designed was 
fairly straightforward, but proved effective in most of the target areas. Each patch 
could hold ~4 µg of antigen (inside of microparticles), was strong enough to penetrate 
skin, and deposited its payload intradermally. The result was a potent immune 
response that was as good as or better than traditional vaccination options, but did not 
require a hypodermic needle and was freeze-dried for easy storage/transport. 
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While the results were promising, many improvements would be needed for such 
a patch to advance towards clinical development. First, future work should consider 
methods for increasing the dose that can be stored and delivered in a single patch. 
This could include simple options such as increasing the number of microneedles per 
patch, utilizing larger needles, or creating microparticles capable of higher antigen 
loading. One of the biggest limitations not only to the microneedle system developed 
here, but to many similar systems, is the efficacy with which the patches deliver their 
dose. Without a pedestal, only 25% of the encapsulated microparticles were delivered. 
Even with a pedestal, this jumped to only 55%, thus effectively wasting half the dose. 
More research is needed to develop optimal pedestals patches, which should possess 
greater mechanical strength than those developed here, with emphasis on a greater 
ability to penetrate the skin more deeply. This also includes possible improvements to 
pedestal geometry, as well as the material used to construct the pedestal and the 
microneedles. The material should be biocompatible, soluble so to leave no potentially 
biohazardous waste, and rapidly disintegrating to reduce application time. Lastly, 
microneedle patches should be evaluated in conjunction with post-application topical 
therapies such as bandages, creams, or ointments. A secondary application could add 
several benefits to the system, such as to aid in wound healing, help retain the 
microparticles in the skin, or even possibly to act as an additional adjuvant and further 
direct the immune response to the application site. 
It is intended that the work outlined in this thesis will act as a base of knowledge 
and experimental proof-of-concept for future studies to expound on the potential of 
Active Self-Encapsulating controlled release systems, as well for inclusion of such 
systems into microneedle patches.  
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Appendix A: Modeling and Predictions of Self-healing Pores in PLGAs 
 
A.1  Abstract 
Self-healing of pores in Poly(lactic-co-glycolic acid)s (PLGAs) plays an important 
role in the encapsulation and controlled release of drugs from PLGA microparticles.  
Despite the importance of this phenomenon, neither the mechanics of the deformation 
nor the material properties that control it have been fully studied. In this study, the 
material properties of PLGA have been characterized using mechanical tests, and a 
finite-element model has been developed to predict how pores heal. This model 
assumes that the healing process occurs by viscous flow resulting from the deviatoric 
stress field induced by the interaction between the surface curvature and the surface 
tension of the PLGA. The simulations, which incorporate measured material properties, 
show good agreement with experimental observations. However, annealing processes 
that occur over prolonged times increase the viscosity and slow the healing times of 
PLGA films at intermediate temperatures above the glass-transition temperature.  
These findings may be reasonably applied towards the prediction of healing processes 
in PLGA and in related biomaterials for important biomedical applications such as 
drug delivery. 
A.2  Introduction 
A.2.1  Motivation 
Poly(lactic-co-glycolic acids) (PLGAs) forms the basis of some of the most widely-
used biomaterials today. Since their first patented use in the 1960s, they now form key 
components of many products that have been approved by the US Food and Drug 
Administration, such as sutures (1), cardiovascular stents (2-4), skin implants (5, 6), 
and a plethora of drug-delivery devices such as microparticles (7-9), patches (10), and 
in-situ forming gels (11). Several characteristics make PLGAs attractive for medical 
applications. They have excellent biocompatibility, and their degradation kinetics and 
mechanical strengths can be easily tailored by altering molecular weights, monomer 
ratios, lactide isomer content, and type of end-capping. In addition, glass-transition 
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temperatures (T
g
) near body temperature result in desirable in vivo release-behavior of 
drug-delivery systems with enhanced shelf-lives. Despite the prevalent use of PLGAs, 
the associated scholarly literature often does not focus on analyses of their material 
properties. There have been reports on the moduli of PLGA products, but very little 
work has been reported on the underlying physics and mechanics of the deformation 
behavior. An understanding of this behavior will become increasingly important as 
PLGA and related materials are used in new ways. Therefore, in the present work, we 
explore the constitutive properties of PLGA, with a focus on developing a model of the 
passive self-healing process in polymers.  
 Autonomous healing in polymers can be achieved by several different strategies.  
For example, “active” methods have been developed that rely on an encapsulated 
healing/filling agent, either in pores or in micro-vascular networks (12-15).  
Alternatively, in the absence of significant tensile stresses, voids and cracks in many 
materials can heal passively as a result of creep / viscous flow driven by surface 
tension. This process requires no chemical modification of the material, and relies only 
on the temperature being sufficiently elevated to ensure flow.  This phenomenon can 
occur in many different applications from self-healing automotive paints (12), to 
erasable data storage (16). A major application of self-healing in PLGAs is the recent 
description of an aqueous-based micro-encapsulation method for bio-macromolecules 
(9). In this case, pores on the surface of PLGA microparticles self-heal to trap bio-
macromolecules inside them, without the need for micronization and organic solvent 
exposure known to be deleterious to proteins. Similarly, healing has also been linked to 
the termination of the initial burst release and long-term release kinetics of PLGA-
encapsulated large molecules (17, 18). 
 Porosity can be introduced in PLGAs as a result of phase transitions and 
associated density changes during curing (19). Furthermore, pore networks in PLGA 
microparticles can be created by the control of osmotic pressure differences induced 
by changes in the internal and external environments.  Healing of these pores is critical 
for the quality of the encapsulation and release of drugs and peptides (9, 18). The 
healing process was explored in a series of model experiments by Mazzara et al. (20) 
using controlled pores that had been artificially introduced into the surface of PLGA 
films by blunt-tip micro-needle arrays. These experiments showed empirically that the 
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healing times were controlled by the visco-elastic properties of the PLGA. In this 
present paper, we extend this work by developing a finite-element model for pore 
healing. The model assumes that healing proceeds by viscous flow in response to a 
deviatoric stress field induced by the surface tension and curvature of the pores. The 
model can be used to describe pore healing in terms of the temperature and geometry.  
It may be useful to explain the results of past self-healing experiments. It may also be 
useful as the basis of a quantitative design to predict healing times corresponding to 
desired controlled release with PLGA dosage forms. 
A.2.2  Theoretical Background 
The underlying assumption of this model is that the pores heal by flow driven by 
internal stress fields established by surface tension effects (21, 22). In this section, we 
summarize the theoretical background of these two phenomena.   
A.2.2.1  Constitutive Models for a Linear Polymer 
The simplest representation of a linear visco-elastic material is known as a 
Maxwell model. The constitutive behavior corresponding to such a model can be 
represented by a spring (with a modulus of E
m
) in series with a dashpot (with a 
viscosity of η
m
). The dashpot represents a single thermally-activated mechanism of 
flow, so the viscosity is of the form 
                                
RTQ
mom
me  ,     (1) 
where Q
m
 is the activation energy of the relaxation mechanism leading to flow, R is the 
molar gas constant, T is the absolute temperature, and η
mo
 is a material constant. The 
characteristic relaxation time (τ
m
) of a Maxwell model is given by 
                     RTQ
mommm
meE
/ 
,
    (2) 
where τ
mo
 is a material constant. A time-dependent modulus, E(t) can be defined for a 
polymer as the ratio of the stress at a given time t that results from a fixed strain: 
                               mtmeEtE
/ ,     (3) 
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The fully-relaxed modulus of a Maxwell solid, given by t  ∞, is zero. This is important 
in the present context, because pore healing can only occur when the fully-relaxed 
modulus approaches zero. 
 While a Maxwell model describes some important characteristics of a polymer 
that exhibits pore healing, polymers generally exhibit more than one relaxation 
mechanism. Some of these mechanisms may allow for complete relaxation of polymer, 
while others may allow only partial relaxation. Each mechanism will have its own 
activation energy and characteristic relaxation time, and can be represented by an 
assembly of elements consisting of linear springs and dashpots. The time-dependent 
deformation of a polymer can then be modeled as the resultant of such an assembly.  
The individual moduli and viscosities that go into such a model are determined by fits 
to the observed response of the polymer at different time scales through experiments 
such as dynamic mechanical analyses (DMA) and stress-relaxation tests, as described 
below. 
A.2.2.2  Role of Surface Energy and Curvature 
The chemical potential of an atom or molecule at the surface of a material 
depends on the product of the surface energy (surface tension) and the local surface 
curvature. Gradients in this potential provide a driving force for the material to change 
its shape, either by diffusion of atoms or molecules along the surface, or by bulk 
deformation in response to deviatoric (shear) stresses established within the body of 
the material. In the present work, we assume that bulk flow is the dominant 
mechanism; this is consistent with the experimental results presented later. 
 The internal stress field associated with a surface (or interface) is established by 
the change in normal stress (σ
n
) across a curved surface, as given by the Young-Laplace 
equation: 
                            21  n ,     (4) 
where γ is the surface tension of the material, and κ
1
 and κ
 2
 are the local principal 
curvatures. A convex surface results in a compressive normal stress at the surface and 
a concave surface results in a tensile stress at the surface. The internal stress field 
induced by surface curvature is exactly equivalent to the stress field induced by 
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applied surface tractions that are normal to the surface and have a magnitude given by 
Equation 1. This equivalence between the stresses induced by surface curvatures and 
those induced by applied surface tractions forms the basis for the analysis used in this 
paper. 
A.2.2.3  Pore Healing 
 The healing of a surface indent is illustrated 
in Fig A1.  The indent is initially formed by the 
application of a localized external pressure during 
indentation of a freshly-spun PLGA film.  This 
creates large deviatoric stresses to which the 
polymer responds by rapidly flowing and forming an 
indent. The effects of surface energy at this stage 
are relatively small compared to the effects of the indentation stress field, so surface 
features such as a lip around the indent can often be retained (20). (Even when the 
indentations are square, the surrounding lip is approximately circular). When the 
indenter is removed and the film dried, deformation is driven by the deviatoric stress 
field that is established by the surface tension and curvatures. (A residual stress field 
resulting from the indentation can also contribute to this deformation; in the present 
work, we assume this is relaxed by flow during the indentation process.)  The resulting 
stress field can be visualized and modeled by considering equivalent surface tractions, 
as shown in the schematic of Fig A1. Provided the fully-relaxed modulus is 
significantly smaller than the stresses induced by the surface curvature, the material 
can flow to smooth out any surface curvatures. Both the depth of the indent and the 
amplitude of any lip formed around the indent will decay over time.  
 For an incompressible linear-viscous material, the deformation field that results 
from a deviatoric stress field can be calculated using the Levy-Mises flow rule (23): 
      
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,          (5) 
where~  and ~  are the von-Mises effective strain rate and stress, and i  and i   (i = 1, 
2, 3) are the principal strain rates and stresses.  In Mazzara et al. (20), this approach 
Figure A1 
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Figure A2 
was used to develop a simple analytical result for healing an isolated spherical pore in 
the middle of a viscous material. The Lamé equations (23) for a spherical pore of 
radius a with an internal pressure of p = -2γ/a, give principal stresses at a distance r 
from the center of the pore of  
          
3
2
3
2
 ;
2
r
a
r
a
rr



   .    (6a) 
The corresponding principal strain rates are given by 
             
r
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r
u
rr 


    ; ,     (6b) 
where u is the radial displacement at a distance r from the center of the pore.  
Recognizing that at r = a, 
  
˙ u a( ) = ˙ a, and that at time t = 0 the initial pore radius is a
o
,
 
it 
was shown (20) that the pore size is given by 
                   


2
t
aa o  ,      (7) 
So, the time to heal a spherical pore is predicted to be 2ηa
o
/γ. 
A.3  Material and Methods 
A.3.1  Numerical Implementation 
In the numerical simulation, the initial pores were 
assumed to be ellipsoidal, with a depth of b
o
, and a half width 
of a
o
, on the surface of a film of thickness H
o
 (Fig A2). The 
radius of the external boundaries, S
o
, were set to a value of 
S
o
/a
o
 = 10 in all simulations. It was demonstrated numerically 
that this value was large enough so that its effect was always 
limited to less than a 2% error in the calculated pore depth. The bottom of the film was 
assumed to be attached to a rigid substrate, but free to expand. The assumption of 
axisymmetric geometries allowed the calculations to be simplified, while retaining the 
essential elements of the experimental studies. Furthermore, since the stresses are 
dependent on local curvatures, there is a very large driving force for any sharp corners 
to be rounded out. This results in a transition to axisymmetric shapes early in the 
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healing process, so that details of the initial geometry have only a limited effect on the 
healing time. Indeed, Mazzara et al. (20) reported that their initially square pores 
quickly became circular. We used our numerical method to analyze cylindrical pores, 
and they evolved fairly quickly into ellipsoidal shapes. However, the initial sharp 
corners in a cylindrical void requires a very dense mesh for finite-element analyses.  
Therefore, ellipsoidal geometries were used to model the pores in the general cases 
presented in this paper.  
 Finite-element analyses were conducted using the commercial package ABAQUS.  
The stress fields resulting from the surface tension were induced in the finite-element 
model by applying tractions to the surface proportional to the sum of the principal 
curvatures (Equation 4). A numerical technique for calculating the curvatures has been 
described by Henann et al. (24). We used a similar approach to calculate the curvatures 
of the axisymmetric surfaces. Such a surface can be described by z = Z(r), where z is 
the height above an arbitrary reference value, and r is the distance from the axis of 
symmetry.  The sum of the two principal curvatures (twice the mean curvature) at any 
point on the surface is given by 
       
      212232
22
21
11
2
rZr
rZ
rZ
rZ





   . (8) 
Thus, the calculation is reduced to a two-dimensional problem. The coordinates of an 
integration point A (r
A
,
 
z
A
), and the coordinates of its two nearest neighboring 
integration points, B (r
B
,
 
z
B
) and C (r
C
,
 
z
C
), can be fitted to a parabola (y'/y
o
 = x'2) in terms 
of a local coordinate system with an origin located at point A and aligned with the 
local normal direction. The sum of the principal curvatures at A is then given by 
                           rny ro  22 ,                      (9) 
where n
r
 is the radial component of the outward normal vector at A. This procedure 
was used to calculate the curvature, and the corresponding surface tractions, at all 
points on a surface. A DLOAD user-subroutine was developed and implemented in 
ABAQUS/Standard. The user-subroutine was verified using the simple geometries of a 
sphere and a cylinder. Mesh and boundary sensitivity studies were conducted 
empirically by changing the size of the mesh and the distance to remote boundaries, 
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and verifying that any influence on the results was significantly less than the 
uncertainty associated with the measurements of the material parameters.  
A.3.2  Material Preparation 
PLGA 50:50 with lauryl-ester-terminated chains, with a weight-averaged molecular 
weight of 55.3 kDa, and average inherent viscosity of 0.61 dL g-1 was provided by Lactel 
Inc. Details of the preparation of the PLGA films were reported by Mazzara et al. (20).  
Briefly, the polymer was dissolved in acetone (27% w/w), and spin-coated onto a 
Teflon-coated glass substrate. The films were dried for one day in a fume-hood at 
room temperature, and then for an additional day under vacuum at room temperature 
to remove excess solvent. When the films were separated from the glass substrate they 
had a final thickness of 16 ± 3 µm (n=3, ± SD).  
A.3.3  Material Characterization 
A.3.3.1  Stress Relaxation Tests 
Dry films were cut into rectangular specimens of approximately 10 mm in width 
and 30 mm in length. Stress-relaxation tests were conducted in a temperature range of 
40 °C to 65 °C using a TA Instruments RSA3 dynamic mechanical analyzer. The samples 
were placed in the grips at room temperature and heated to the desired temperature at 
100 °C min-1. One minute was allowed for the temperature to stabilize before a strain of 
3 % was applied within 5 ms. The strain was held constant, and the corresponding 
stress was then measured every 0.01 second.   
A.3.3.2  Dynamic Mechanical Analysis 
The same instrument was used to measure the visco-elastic properties of the 
PLGA films by dynamic mechanical analysis (DMA). Samples were tested in uniaxial 
tension at a frequency of 1 Hz, with a strain amplitude of 0.1% and an initial mean 
force of 0.01 N. The storage modulus, E', loss modulus, E'', and loss tangent, tanδ, were 
measured over a temperature range of 25 °C to 70 °C, with a temperature ramp-up rate 
of 3 °C min-1 and a soak time of 30 seconds to reach steady state at each temperature.  
Three identical samples were analyzed to determine representative values and 
uncertainties.  
 Frequency sweep tests in the range of 0.001 Hz to 99 Hz with a strain amplitude 
of 0.1% were then conducted in a temperature range of 25 °C to 65 °C. The mean strains 
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Figure A3 
in these cyclic tests were set to be 25% greater than the strain amplitudes to ensure 
that the specimen never went into compression. The storage modulus, loss modulus 
and tanδ were determined as functions of frequency. 
A.3.3.3  Measurement of Surface Tension 
The surface tensions of the PLGA films were determined by placing a drop of 
water on the films and using a goniometer to measure the polymer-water contact 
angle. Contact angles for each film were measured in three distinct locations, and a 
minimum of two samples were used for each set of conditions. The contact angles 
were used to calculate the tension, γ, following Berthelot’s combining rule (25) 
                   4/cos1 2 lv  ,     (10) 
 where θ is the contact angle, and γ
lv
 is the surface tension of water.  
A.3.3.4  The Effects of Annealing and the Kinetics of Solvent Escape 
To investigate the effects of annealing and annealing time on the visco-elastic 
properties of the PLGA, films were incubated at three temperatures (50 °C, 55 °C and 
65 °C) above the T
g
 for various times. The properties of these films were tested using 
DMA and relaxation tests, as described above. 
 To quantify the kinetics of annealing and solvent escape, the films were 
subjected to thermo-gravimetric analysis (TGA). Approximately 20 mg of PLGA was 
placed on platinum pans and quickly heated (50 °C/min) to 50 °C, 55 °C and 65 °C. The 
films were held isothermally for 8 hours, and the percent change in mass was 
recorded. Note that glass-transition temperature data for these films were reported in 
our previous work (20). 
A.4  Results 
A.4.1  Validation of Finite-element Model 
Equation (7) gives the analytical solution for the radius 
of a spherical pore in an infinite body of an incompressible 
Maxwell solid as a function of time. As a check on the validity 
of our numerical technique, we repeated this calculation 
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numerically, using the finite-element model discussed above. A comparison between 
the simulation and the analytical results is presented in Fig A3, showing that the finite-
element model gives the expected result. It should be noted that, in this case, the 
numerical calculations suffer from excessive distortion of the mesh when the pore is 
very small, owing to the huge normal stresses acting at the surface. For this reason, the 
numerical calculations shown in Fig A3 could not be taken all the way to complete 
pore healing.  
A.4.2  Numerical Results for Surface Pores 
Fig A4(a) shows how the depth of an initially ellipsoidal surface pore evolves with 
time for a Maxwell material. It should be noted that, in contrast to the healing of a 
spherical pore inside a polymer, the depth of the pore goes to zero only 
asymptotically. There is no well-described healing time. Instead, the healing time must 
be defined in terms of how long a pore takes 
to heal to a given percentage of its original 
depth.  Experimentally, this will be the depth 
at which the pore can no longer be 
distinguished. Unless stated otherwise, we 
use a fixed percentage of 85% to define 
healing in the numerical simulations, since 
this corresponds to the point at which the 
healing rate starts to decay markedly. This 
arbitrary definition introduces a systematic 
error into absolute comparisons with 
experimental data for healing times; however, 
it is expected that relative comparisons will 
be unaffected as all the simulations will be 
affected equally. 
 The change in the cross-sectional profile of an axisymmetric surface pore with 
time is shown in Fig A4b.  This set of images corresponds to the simulation for which 
a
o
/b
o
 = 1 in Fig A4a.  The full animated clip from which these images are taken can be 
found in the supplementary material. 
Figure A4 
(b) 
(a) 
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A.4.3  Effect of Temperature on Healing of Wet Films 
We did not have the capability to do DMA and stress-relaxation tests in an 
aqueous environment. However, the results presented by Mazzara et al. (20) for the 
healing of pores in wet films as a function of temperature were used as a preliminary 
validation of the physics of the model. An activation energy of 193 kJ mol-1 for the 
viscosity of the wet PLGA films was found by fitting the healing 
data to an Arrhenius plot in Ref. (20). This value of activation 
energy was used in our finite-element calculations, with a 
representative value of Young's modulus E = 1 GPa.  
(This choice of modulus was not important for the calculations, 
but it is consistent with the measured value for a dry PLGA 
film, as described later). It is important to note that the 
activation energy and T
g
 of
 
these hydrated films were 
suppressed compared to those of the dry films, owing to 
plasticization of the polymer by water (20). 
 The pores in the wet PLGA had an initially square cross 
section, and an initial width-to-depth ratio of a
o
/b
o
 = 5/14. By 
fitting the observed healing time for these pores at one arbitrarily chosen temperature 
of 53 °C to the numerical predictions for ellipsoidal pores with the same aspect ratio to 
heal to 85%, and using an activation energy of 193 kJ mol-1 for the viscosity, a value for 
γ/η
o
 could be determined as 7.9 ± 2.3 x 1021 m s-1. This fitted value of γ/η
o
 was then 
used in conjunction with the activation energy of 193 kJ mol-1 for the viscosity in the 
finite-element model to calculate the healing time for identical pores over a range of 
temperatures. A comparison between the predicted healing times and the temperature 
is shown in Fig A5a.   
 The role of the initial aspect ratio and volume on healing time was also 
investigated experimentally in Ref. (20).  The material parameters described above 
were incorporated into a finite-element calculation, and used to predict the healing 
time (again, defined as an 85% reduction in depth) for differently shaped pores.  These 
predictions are shown in Fig A5b, and compared with the experimental observations.  
It should be emphasized that this comparison, unlike that of Fig A5a, does not reflect 
Figure A5 
(a) 
(b) 
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any fits to the data.  Therefore, the reasonable agreement between the predictions and 
experimental results provides support for the modeling. 
A.4.4  Measurement of Properties for Pry PLGA Films 
A.4.4.1  Stress Relaxation  
In the study described above, 
the material properties for wet PLGA 
films were determined from fits to 
experimentally observed data, and 
then used to calculate pore healing.  
While this shows consistency 
between the model and the experimental observations, a much more important 
question is whether it is possible to measure the material properties independently of 
the pore-healing experiments, and to use these properties in a numerical model to 
predict the healing behavior. This was the goal of the studies on the dry PLGA films for 
which it was possible to measure the properties. 
 An initial assumption was that the PLGA behaves in these stress-relaxation tests 
as a simple Maxwell solid with a time-dependent modulus as given by Equation 3. This 
equation shows that a log-linear plot of the time-dependent modulus against time 
should be of the form of a straight line with a slope of -τ
m
.   
 Experimental plots for the time-dependent modulus are shown in Fig A6(a) for 
the temperature range of 40 °C to 65 °C. These plots show a very fast initial relaxation 
of the time-dependent modulus followed by a slower decrease. If we assume that PLGA 
is a linear polymer, this initial rapid drop indicates at least one additional relaxation 
mechanism with a relatively short time constant. The time constant for this fast 
relaxation was too small to be extracted reliably from the stress-relaxation data of Fig 
A6(a); however, it was determined by means of DMA, as described later. At longer time 
scales, there does appear to be a single dominant mechanism that gives a constant 
slope to the stress-relaxation curves. The slopes of these lines corresponding to 
different temperatures were determined by a least-squares fit process, and plotted on 
an Arrhenius plot in the form of log(τ
m
) against 1/T in Fig A6(b). The slope of this line 
Figure A6 
(a) (b) 
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indicates an activation energy of Q
m
 = 206 ± 6 kJ mol-1, and a pre-exponential term of 
τ
mo
 = 6.4 ± 0.2 x 10-32 s.  It can be observed that at all temperatures, the constant slope 
at long time scales starts when the time-dependent modulus is in the range of 
1.5 ± 0.5 MPa.  Using this value of the modulus for E
m 
in the Maxwell model, Eqns. (1) 
and (2) can be used to deduce a value of η
mo
 = 9.6 ± 3.5 x 10-32  MPa·s.  
A.4.4.2  Dynamic Mechanical Analysis 
The storage modulus and loss tangent for dry PLGA films computed from DMA 
temperature-sweep tests at 1 Hz are plotted in Fig A7(a). From this plot, the unrelaxed 
modulus is estimated to be 1.6 ± 0.3 GPa, being the asymptotic level that the storage 
modulus tends to at low temperatures. It should be noted from Fig A7(a) that the peak 
in tanδ is a double peak. The first peak is at about 38 °C, which is consistent with the 
estimate of Mazzara et al. (20) for a T
g
 between 35 °C and 40 °C. Here, we will neglect 
the fine details of the relaxation peak, and assume a single relaxation mechanism that 
operates at 1 Hz over the temperature range of 38 °C to 48 °C.  
 To extract the visco-elastic properties of the relaxation mechanisms that caused 
the fast initial relaxations observed in the stress relaxation tests, we conducted 
frequency sweep tests. Representative results of the tests are shown in Fig A7(b). The 
results show single peaks in the loss modulus, and they can be interpreted based on a 
standard-linear-solid (SLS) model. Such a model results in a time-dependent modulus 
of the form (26) 
                                stsr eEEtE
/ .    (11) 
In this equation, the fully-relaxed modulus, E(∞), is given by E
r
, and the unrelaxed 
modulus, E(0) is given by E
r 
+ E
s
. The temperature-sweep tests gave a value for this 
unrelaxed modulus of E(0) = 1.6 ± 0.3 GPa.   
 A standard-linear solid also has a viscosity of the form  RTQssos /exp  , 
where Q
s
 is the activation energy and η
so
 is a material constant. The storage modulus, 
E'(ω), and loss modulus, E''(ω), of an SLS are given by (26): 
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where ω is the angular frequency of the input strain, and the time constant is τ
s
 = η
s 
/ 
E
s
. The loss modulus is maximal at ω=1/τ
s
, so the time constants at different 
temperatures can be extracted from the peaks in the loss modulus. These are plotted 
as an Arrhenius plot in Fig A7(c). From this plot, the activation energy was determined 
to be Q
s
 = 250 ± 29 kJ mol-1, and the pre-exponential term, τ
so
 = η
so 
/ E
s
, was determined 
to be 6.6 ± 0.8 x 10-44 s.  
The fully-relaxed modulus, E
r
, of a standard-linear solid 
can be determined from the difference between the storage 
and loss modulus at the frequency corresponding to the 
maximum loss modulus (Equation 12 A and B). In the present 
case, there was a slight dependence of the relaxed modulus on 
temperature. This indicates the presence of additional fast 
relaxation mechanisms, which are ignored in the present 
analysis.  However, the relaxed moduli measured from the 
peaks in the loss modulus are consistent with the value of 
1.5 ± 0.5 MPa determined from the stress-relaxation 
experiments for E
m
. 
Combining the results from the stress-relaxation tests 
and the frequency-sweep tests, we propose a material model 
for dry PLGA films as shown in Fig A8(a). The model consists 
of a standard-linear solid in series with a dashpot, and has a 
time-dependent modulus of  
        ms ttsr eeEEtE  //  .                                                   (13) 
(a) 
(b) 
(c) 
Figure A7 
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In this model, the standard-linear solid provides a time-
dependent initial modulus for the Maxwell dashpot. The 
parameters for the different elements of the model are 
summarized in Table 1. The Maxwell dashpot with a 
viscosity of η
m
 dominates the healing process and is the one 
we are particularly interested in when analyzing the healing 
process. The dashpot associated the standard-linear solid, with a viscosity η
s,
 is 
associated with relaxing 99.9% of the instantaneous modulus, but it has no significant 
effect on healing. When this model is used in a finite-element code, it needs to be 
converted to the form shown in Fig A8(b), which is the equivalent Prony-series 
representation. In this figure, E
1
 = E
s
, E
2
 = E
m
, η
1
 = (1/η
 s
+ 1/η
 m)
-1, and η
 2
 = η
 m
.  A Prony-
series representation requires a non-zero fully-relaxed modulus. Therefore, an 
arbitrary value of E
3
 was chosen that was sufficiently low so as not to impede the 
healing.  
 
 
A.4.4.3  Interfacial Tension for Dry PLGA 
The water-polymer contact angle for the PLGA films used above was measured to 
be 71.8 ± 1.4°
.
  Using the Berthelot combining rule and a water-air interfacial tension of 
72.70 mN m-1 (25), the surface energy of dry PLGA films was calculated to be 
γ
 
= 31.0 ± 2.0 mN m-1.  
A.4.5  Prediction of Healing Himes for Pores in Dry PLGA Films 
Finite-element calculations of pore healing in dry PLGA films using the material 
properties described above were performed.  Axisymmetric ellipsoidal pores with an 
aspect ratio a
o
 / b
o 
= 2.5/7 and a pore volume of 91.6 µm3 were used to match the 
values from the experimental study (20).  The predicted healing times are plotted as a 
Es [MPa] (1.6 ± 0.3) x 10
3
 
Er [MPa] 1.5 ± 0.5 
 o [MPa
.s] Q (kJ mol
-1) 
s  (1.1 ± 0.3) x 10
-40   
250 ± 29 
m (9.6 ± 3.5) x 10
-32 
206 ± 6 
Figure A8 
Table A1: Values of parameters of the unannealed dry PLGA (See Fig. A8a) 
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Figure A9  function of temperature in Fig A9, along with the 
experimental results. Three different contours of different 
healing levels are plotted in Fig A9, showing the effect of 
small changes in the definition of healing.   
A.5  Discussion 
While Fig A9 shows that the numerical predictions are 
generally consistent with the experimental observations, 
the experimental healing times appear to be significantly longer than expected at lower 
temperatures. It is conjectured that this is a result of changes in material properties 
associated with annealing, as a result of relatively long healing times at low 
temperatures. In particular, the films used in the study had significant residual solvent 
content. This excess solvent acts as a plasticizer for the polymer, effectively decreasing 
its viscosity and T
g
 (27). Consequently, any loss of this solvent over long periods of 
times may cause an increase in the viscosity and T
g
 and a corresponding increase in 
the healing times. This is consistent with the common observation of a higher T
g
 
during the second heating cycle of differential scanning calorimetry (20).  
 To elucidate the effects of annealing, samples of the PLGA were held 
isothermally in a TGA experiment for 8 hours at temperatures of 50 °C, 55 °C and 65 °C 
(Supplementary Fig A1). The initial rate of solvent evaporation increased with 
temperature. However, after two hours, there was no significant further evaporation, 
and the final weigth loss indicated that the initial residual solvent content had been 
about 1.7%.  The weight loss during the first one hour was fitted to the equation: 
               Atloss eCtw  11  ,     (14) 
where C
1
 is a constant, which is the asymptotic value of the weight of the evaporated 
solvent at long time scales, and A is a temperature-dependent rate parameter. By 
fitting the data within the first hour (when most drastic weight loss occurs) using 
Equation 14, and plotting the parameter A on an Arrhenius plot, the activation energy 
of this solvent escape process was determined to be 55 ± 1.3 kJ mol-1.   
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 The most important visco-elastic property of the films, from the perspective of 
pore healing, is the viscosity represented by the second dashpot (η
m
) in Fig A8a. The 
effects of annealing on viscosity were investigated by holding the films isothermally at 
65 °C for up to two hours.  DMA was then used to measure the T
g
, and stress-relaxation 
measurements were used to determine the viscosity. These results showed that 
annealing raised the T
g
, increased the viscosity and dropped the activation energy, but 
the instantaneous modulus was not significantly affected. These changes are 
summarized in Table A2 for different annealing times at 65 °C. It should be noted that 
the time scales over which the relaxation data were obtained (see Fig A6a, for example) 
were much smaller than the time scales over which significant annealing might occur. 
Therefore, it is believed that annealing did not occur while the relaxation data were 
being collected.  
 
 In addition to changes in the bulk properties of the 
PLGA, measurements of the contact angle suggested that 
the polymer-air interfacial tension may also change 
significantly as a result of solvent evaporation and 
annealing. In particular, annealing at 65 °C for two hours 
gradually reduced the interfacial tension from  
31 ± 2 mN m-1 to 25 ± 3 mN m-1. 
 Finite-element simulations of pore healing were 
performed using the most extreme values of the material properties given in Table A2 
(to provide an upper bound on the healing time). These results are presented in  
Fig A10. As can be seen from this figure, while the use of the unannealed properties 
provide excellent predictions for the behavior at high temperatures, the use of 
Annealing time [hours] 
Tg [°C] 
mo [MPa
.s] Qm [kJ mol
-1] 
0 38.4 ± 0.3 (9.6 ± 3.5) x 10-32 206 ± 6 
0.5 47.0 ± 0.3 (2.0 ± 0.2) x 10-20 140 ± 10 
1 49.5 ± 0.3 (2.0 ± 0.2) x 10-22 150 ± 10 
2 50.8 ± 0.3 (2.8 ± 0.2) x 10-22 150 ± 10 
Table A2: Parameters for the dry PLGA after annealing at 65 °C. 
Figure A10 
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annealed properties provide better predictions at the lower temperatures.  At the 
higher temperatures, the total time required to heal the film is comparable to the 
annealing time, so most of the healing occurs before full annealing. However, at lower 
temperatures, the time scales for annealing are smaller than the time scales for 
healing, so the results are more affected by the annealing. This is expected since the 
activation energy for solvent evaporation of 55 ± 1.3 kJ mol-1 is smaller than the 
activation energy for viscous flow. The differences between the simulations for an 
annealed and unannealed film reflect different values for surface tension, viscosity, 
and T
g
, all of which appear to change during annealing of a film.  
 In many materials, surface pores can also heal by surface diffusion; for example, 
this is the mechanism often ascribed to the healing of pores in high-temperature 
ceramics (28-30). However, this does not appear to be the case for PLGA.  First, the 
healing data does seem to be quite well described by the visco-elastic properties of the 
PLGA.  Second, surface diffusion tends to have a lower activation energy than the bulk 
diffusive processes responsible for flow. This would decrease the healing time at low 
temperatures below that predicted from viscous flow. The opposite trend was 
observed, so the discrepancy in healing times is not a result of surface diffusion; 
rather it is a result of solvent evaporation, as discussed above.   
Finally it is interesting to consider how these changes might correlate to pore 
healing in PLGA microparticles. These are generally dried to remove excess water and 
solvent, so there is expected to be a low solvent content during incubation. However, 
water is known to plasticize PLGA so, upon hydration of the polymer, the glass-
transition temperature would drop, as it does in the presence of residual solvent.  
Furthermore, the pores in the microspheres can vary considerably in size, from 
roughly 10 nm up to 10 µm. These compound effects of variability in T
g
 and a range of 
pore sizes, would make the application of the analysis presented here to PLGA 
microspheres a logical application to model the influence of healing on the long-term 
release of macromolecules.  
A.6  Conclusions 
Self-healing in PLGA can be modelled by viscous flow driven by internal stress 
fields established by surface-tension effects. A finite-element model incorporating a 
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numerical method to calculate the evolution of surface curvatures was developed to 
analyze indent healing in visco-elastic materials. The rate of healing for surface pores 
decreases as the pores heal, with the pore depth approaching zero asymptotically.  The 
visco-elastic properties of PLGA films were characterized using a combination of DMA 
and stress-relaxation tests. The dry PLGA films used in this study had a relatively high 
instantaneous modulus of 1.6 ± 0.3 GPa, and a glass transition temperature of  
38.4 ± 0.3 °C, owing to reduced solvent content. The PLGA displayed relaxation 
mechanisms with at least two distinct time scales. The first mechanism is a fast one 
with a very short time constant; this reduced the modulus by 99.9% at a time scale of 
less than a minute at temperatures above glass transition temperature, leaving the film 
with a partially-relaxed modulus of 1.5± 0.5 MPa. This modulus, although much 
smaller than the instantaneous modulus, is still too large for healing to occur. A 
second relaxation mechanism with a much longer time constant was responsible for 
viscous flow that could accommodate pore healing.   
 Finite-element simulations of indent healing using material properties that had 
been independently measured were broadly consistent with earlier experimental 
observations reported by Mazzara et al. (20). It was noted that annealing of the films, 
which is associated with solvent evaporation, resulting in longer healing times than 
expected at lower temperatures.  
Since the healing mechanism is thermally activated, temperature is one of the 
most important factors in self-healing of PLGA. The temperature needs to be high 
enough for viscous flow to occur during the time scales of interest. In addition to the 
temperature, the indent geometry also affects healing time, with larger indents 
requiring longer time to heal. While this present study has focused on the healing of 
indents as a model for surface pores in PLGA films, we believe that the numerical tools 
used to analyze the process and the experimental techniques used to deduce the 
relevant material properties will be appropriate for predicting the pore-healing 
processes of significance for pharmaceutical use of these materials.   
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A.9  Figure Captions 
Figure A1  Self-healing in PLGA. a) A schematic illustration of the healing process showing the 
shape-recovery of a surface pore driven by stress fields arising from surface curvature. The stress fields 
can be mimicked by the application of surface tractions that are proportional to local curvatures.  
b) Micrographs of self-healing of pores introduced by indentation of a PLGA film when incubated at 65 °C.  
c) Self-healing of surface pores in PLGA microparticles used in controlled release. The left image is after 
fabrication using the solvent evaporation method as previously described (9), and the right image is after 
incubation in solution at 42 °C (above Tg) for 48 hours. 
Figure A2  a) A schematic illustration of an axisymmetric ellipsoidal surface pore. b) The 
axisymmetric geometry used in the numerical simulations.  The boundaries are located at an outer radius 
of So, which is big enough so that the pore can be considered as an isolated pore. The thickness of the 
substrate is Ho.  The bottom symmetry plane models free sliding on a rigid substrate.  
Figure A3  The results of a numerical calculation of the healing time of a spherical pore in an infinite 
visco-elastic body agree with the analytical results.  The numerical results are affected by the excessive 
distortion when the residual radius of the pore is small, resulting in larger uncertainties, as represented by 
the error bars.   
Figure A4  (a) Numerical results showing how the residual depth of an ellipsoidal surface pore in a 
Maxwell material varies as a function of time; these results illustrate how the rate of healing slows down 
as the pore depth decreases. In this plot, the time, t, has been normalized by the surface tension, γ, the 
viscosity, η, and the initial volume of the pore, Vo.  Wider and shallower pores, of the same initial volume 
require longer times to reach the same level of healing. The error bars on these plots correspond to 
numerical uncertainties associated with mesh size. (b) Numerical results showing how the cross-sectional 
profile of a surface pore evolves with time.  This images are taken from the simulation used to generate 
the data of Fig A4a, with ao/bo = 1.  
Figure A5  (a) A comparison between the calculated time to heal pores in a wet PLGA film 
(Tg = 23.4 ± 0.4 °C) and the experimental observations of Mazzara et al. (20), as a function of 
temperature.  The geometrical parameters of the ellipsoidal pore used in the numerical calculations were 
ao/bo = 5/14, So/ao = 10, and Ho/bo = 25/7.  These were consistent with the experimental geometries that 
had pores with an initially square cross section. The material properties were chosen to fit the 
experimental results at 53 °C, and an activation energy of 193 kJ mol
-1
 for the viscosity had been 
previously estimated from an Arrhenius fit to these data (20). The uncertainty in the numerical simulations 
(represented by the dashed lines) matches the uncertainty from the experimental results at 53 °C. (b) 
Good agreement is shown between the predicted and experimentally-observed effects of pore volume 
and aspect ratio on healing time. The experimental data are from Mazzara et al. (20), and the parameters 
for the numerical studies were identical to those used for Fig A5(a). The uncertainty in the numerical 
simulations (represented by the dashed lines) comes from the uncertainties to the fit in Fig A5(a). 
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Figure A6  (a) Sample data of stress relaxation tests for dry PLGA films at different temperatures for 
an initial strain of 3%, using a TA Instruments RSA3 dynamic mechanical analyzer. While the plot for a 
single thermally-activated relaxation is a straight line, the initial change in slope indicates additional rapid 
relaxation mechanisms. Only the longer-scale relaxation data were obtained from this plot.  The constant 
slope associated with this longer time scales starts when the time-dependent modulus is 1.5 ± 0.5 MPa. 
(b) The time constant, tm, obtained from the data of Fig A6(a) decreases as the temperature, T, increases.  
An Arrhenius plot of relaxation time against 1/T shows an activation energy of 206 ± 6 kJ mol
-1
 for the 
viscosity term responsible for the slow relaxation in the temperature range of 40 °C to 65 °C.  The data 
also indicate that the pre-exponent for the time constant (Equation 2) is given by tmo = 6.4 ± 0.2 x10
-32
 s. 
Figure A7  (a) Temperature dependence of storage modulus and loss tangent determined by DMA 
for dry PLGA films. The tests were conducted at a constant frequency of 1 Hz. Three samples were 
tested, and the average value has been plotted.  The double peaks in tanδ indicate at least two relaxation 
mechanisms with similar time constants in the temperature range, which can be approximated by one 
equivalent dashpot. The unrelaxed storage modulus is estimated to be 1.6 ± 0.3 GPa. (b) Representative 
data from DMA frequency sweep test showing the storage and loss modulus as functions of frequency for 
dry PLGA films at 30 °C. The loss modulus presents with a single peak within the range of frequency 
analyzed, and can be interpreted based on a standard linear solid model. The time constant can be 
calculated from the peak in the loss modulus, as explained in the text. (c) The time constant obtained 
from data such as that shown in Fig A7b decreases as the temperature, T, increases. An Arrhenius plot 
shows an activation energy of 250 ± 29 kJ mol
-1
 for the fast relaxation. The pre-exponent for the time 
constant (Equation 2) is given by τso= 6.6 ± 0.8 x 10
-44 
s. 
Figure A8  Proposed material model for PLGA. (a) The model consists of a standard linear solid in 
series with a dashpot.  The standard linear solid series provide a time-dependent initial modulus for the 
lower dashpot. The material has a fully-relaxed modulus of zero, ensuring complete healing to occur. The 
lower dashpot is the dominant relaxation mechanism at longer time scales. (b) The equivalent model 
used as a Prony series for finite element calculations in ABAQUS, with  
E1 = Es, E2 = Er, η1 = (1/ηs + 1/ηm)
–1
, and η2 = ηm. E3 was arbitrarily chosen for the implementation of the 
Prony series, and was sufficiently small so as not to impede healing. 
Figure A9  The predicted time to heal a surface pore in dry PLGA films, using the material properties 
obtained in this study.  Three different definitions of healing, 83%, 85% and 87% are shown to illustrate 
the sensitivity of the results to the definition of healing.  The predicted results are in good agreement with 
the experimental observations at high temperatures, but predict too short a healing time at lower 
temperatures. 
Figure A10  The predicted time to heal a surface pore in annealed PLGA films, using the annealed 
properties of the PLGA.  The annealed properties provide a better match for the predictions at low 
temperatures, while the un-annealed properties provide a better match at higher temperatures.  This is 
consistent with the notion that the long healing times at low temperatures allow annealing to occur, and 
the corresponding loss of solvent reduces the viscosity of the PLGA.  
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Supplementary Data 
Figure AS1 The weight of dry PLGA films measured as a function of time when held at 50 °C, 55 °C, 
and 65 °C.  The relative weight change percentage of evaporated solvent after 8 hours of treatment was 
1.9 ± 0.2%. 
 
Supplementary Movie A1: Simulated healing of a surface pore in a Maxwell film. The pore geometry 
used was ao/bo=1. The corresponding pore depth as a function of time can be found in Fig A4a. This 
movie can be viewed at 
http://www.sciencedirect.com.proxy.lib.umich.edu/science/article/pii/S0168365915001352.  
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